WHO Drug Information, Vol. 29, No. 1, 2015                            Recommended INN: List 73




International Nonproprietary Names
for Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names: List 73
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of
Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health
Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4
(EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary
Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does
not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in
Cumulative List No. 15, 2011 (available in CD-ROM only).



Dénominations communes internationales des Substances
pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES: Liste 73
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du
choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques
[Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9);
résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation
mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de
l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–109) et
recommandées (1–70) dans la Liste récapitulative No. 15, 2013 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales para las Sustancias
Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS: Lista 73
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones
Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud,
1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4
(EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las
denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones
Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las
Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se
encuentran reunidas en Cumulative List No. 15, 2013 (disponible sólo en CD-ROM).




                                                                                                  61
Recommended INN: List 73                       WHO Drug Information, Vol. 29, No. 1, 2015




 Latin, English, French, Spanish:   Chemical name or description; Molecular formula;
 Recommended INN                    Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule
                                    développée
 DCI Recomendada
                                    Nombre químico o descripción; Fórmula molecular;
                                    Fórmula desarrollada




 abrilumabum #
 abrilumab                            immunoglobulin G2-kappa, anti-[Homo sapiens integrin
                                      ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin
                                      α4β7, lymphocyte Peyer's patch adhesion molecule 1,
                                      LPAM-1)], Homo sapiens monoclonal antibody;
                                      gamma2 heavy chain (1-444) [Homo sapiens VH(IGHV1-
                                      24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -
                                      IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 (229-
                                      337), CH3 (338-442), CHS (443-444)) (119-444)], (132-
                                      214')-disulfide with kappa light chain (1'-214') [Homo
                                      sapiens V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01)
                                      [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (220-
                                      220'':221-221'':224-224'':227-227'')-tetrakisdisulfide

 abrilumab                            immunoglobuline G2-kappa, anti-[Homo sapiens intégrine
                                      ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine
                                      α4β7, récepteur d’adressage spécifique des plaques de
                                      Peyer, LPAM-1)], Homo sapiens anticorps monoclonal;
                                      chaîne lourde gamma2 (1-444) [Homo sapiens (IGHV1-
                                      24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -
                                      IGHG2*01 (CH1 (119-216), charnière (217-228), CH2
                                      (229-337), CH3 (338-442), CHS (443-444)) (119-444)],
                                      (132-214')-disulfure avec la chaîne légère kappa (1'-214')
                                      [Homo sapiens V-KAPPA (IGKV1-12*01 (95.80%) -
                                      IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                      dimère(220-220'':221-221'':224-224'':227-227'')-
                                      tétrakisdisulfure

 abrilumab                            inmunoglobulina G2-kappa, anti-[Homo sapiens integrina
                                      ITGA4_ITGB7 (integrina alfa4 (CD49d)_beta7, integrina
                                      α4β7, molécula de adhesión específica de linfocitos de las
                                      placas de Peyer, LPAM-1)], anticuerpo monoclonal de
                                      Homo sapiens;
                                      cadena pesada gamma2 (1-444) [Homo sapiens (IGHV1-
                                      24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -
                                      IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 (229-
                                      337), CH3 (338-442), CHS (443-444)) (119-444)], (132-
                                      214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                                      sapiens V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01)
                                      [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero(220-
                                      220'':221-221'':224-224'':227-227'')-tetrakisdisulfuro




62
WHO Drug Information, Vol. 29, No. 1, 2015                                       Recommended INN: List 73



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKVSGYTLS                  DLSIHWVRQA       PGKGLEWMGG        50
                                       FDPQDGETIY AQKFQGRVTM TEDTSTDTAY                  MELSSLKSED       TAVYYCATGS       100
                                       SSSWFDPWGQ GTLVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSNFGTQTYT       200
                                       CNVDHKPSNT KVDKTVERKC CVECPPCPAP                  PVAGPSVFLF       PPKPKDTLMI       250
                                       SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE                  VHNAKTKPRE       EQFNSTFRVV       300
                                       SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE                  KTISKTKGQP       REPQVYTLPP       350
                                       SREEMTKNQV SLTCLVKGFY PSDIAVEWES                  NGQPENNYKT       TPPMLDSDGS       400
                                       FFLYSKLTVD KSRWQQGNVF SCSVMHEALH                  NHYTQKSLSL       SPGK             444

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS VSASVGDRVT ITCRASQGIS                  SWLAWYQQKP       GKAPKLLIYG 50
                                       ASNLESGVPS RFSGSGSGTD FTLTISSLQP                  EDFANYYCQQ       ANSFPWTFGQ 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          145-201      258-318    364-422
                                                              22''-96'' 145''-201'' 258''-318'' 364''-422''
                                       Intra-L (C23-C104) 23'-88'         134'-194'
                                                              23'''-88''' 134'''-194'''
                                       Inter-H-L (CH1 10-CL 126) 132-214' 132''-214'''
                                       Inter-H-H (h 4, h 5, h 8, h 11) 220-220'' 221-221'' 224-224'' 227-227''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       294, 294''



 acorafloxacinum
 acorafloxacin                         7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-
                                       1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-
                                       1,4-dihydroquinoline-3-carboxylic acid

 acorafloxacine                        acide 7-[(3E)-3-(2-amino-1-fluoroéthylidène)pipéridin-1-yl]-
                                       1-cyclopropyl-6-fluoro-8-méthoxy-4-oxo-
                                       1,4-dihydroquinoléine-3-carboxylique

 acorafloxacino                        ácido 7-[(3E)-3-(2-amino-1-fluoroetilideno)piperidin-1-il]-
                                       1-ciclopropil-6-fluoro-8-metoxi-4-oxo-1,4-dihidroquinolina-
                                       3-carboxílico

                                       C21H23F2N3O4


                                                                        OCH3
                                          F                   N                   N


                                       H2N                    F                            CO2H
                                                                                 O


 acumapimodum
 acumapimod                            3-[5-amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl]-
                                       N-cyclopropyl-4-methylbenzamide

 acumapimod                            3-[5-amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl]-
                                       N-cyclopropyl-4-méthylbenzamide

 acumapimod                            3-[5-amino-4-(3-cianobenzoil)-1H-pirazol-1-il]-N-ciclopropil-
                                       4-metilbenzamida




                                                                                                                                 63
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015


                           C22H19N5O2

                                                                                   O
                                         O                        N
                                                                  N
                                     N
                                     H                                                                    N
                                                                          NH2
                                                                  CH3



 albenatidum #
                            3.34
 albenatide                S -{1-[(23S)-23-{[exendin-4 Heloderma suspectum
                           precursor-(48-86)-peptidyl (exenatidyl)]amino}-3,12,24-
                           trioxo-7,10-dioxa-4,13,18,25-tetraazapentacosyl]-
                           2,5-dioxopyrrolidin-3-yl}human serum albumin.
                           Peptide is synthetic, and human serum albumin is
                           produced in Saccharomyces cerevisiae.
                            3.34
 albénatide                S -{1-[(23S)-23-{[précurseur de l’exendin-4 de
                           Heloderma suspectum-(48-86)-peptidyl
                           (exénatidyl)]amino}-3,12,24-trioxo-7,10-dioxa-4,13,18,25-
                           tétraazapentacosyl]-2,5-dioxopyrrolidin-3-yl}albumine
                           sérique humaine.
                           Le peptide est synthétique et l'albumine sérique humaine
                           est produite par Saccharomyces cerevisiae.
                            3.34
 albenatida                S -{1-[(23S)-23-{[precursor de la exendina-4 de
                           Heloderma suspectum-(48-86)-peptidil (exenatidil)]amino}-
                           3,12,24-trioxo-7,10-dioxa-4,13,18,25-tetraazapentacosil]-
                           2,5-dioxopirrolidin-3-il}albúmina sérica humana.
                           El péptido es sintético y la albúmina sérica humana la
                           produce el Saccharomyces cerevisiae.
                           Human Albumin / Albumine humaine / Albumina humana
                           DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV                                   KLVNEVTEFA       50
                           KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC                                   CAKQEPERNE       100
                           CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY                                   EIARRHPYFY       150
                           APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK                                   ASSAKQRLKC       200
                           ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK                                   VHTECCHGDL       250
                           LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI                                   AEVENDEMPA       300
                           DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD                                   YSVVLLLRLA       350
                           KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ                                   NCELFEQLGE       400
                           YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH                                   PEAKRMPCAE       450
                           DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA                                   LEVDETYVPK       500
                           EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT                                   KEQLKAVMDD       550
                           FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL                                                         585

                           Exenatidyl / Exénatidyl / Exenatidil
                           HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS-                                                    39

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279 278-289
                           316-361 360-369 392-438 437-448 461-477 476-487 514-559 558-567

                           Modified residues / Résidus modifiés / Restos modificados             O
                                                          O
                                                                                   H                              H
                                   C                          O                    N                 N
                                   34             HN                       O                                  S       H
                             Exenatidyl-                              H
                                                                      N                    O              O
                            Lys-linker-Cys                                                                    H2 N    CO2H

                                                  R = exenatidyl                   H
                                                                           R               NH2
                                                                               N
                                                      O                        H                             H3C
                                 S           HO                                        O
                              58 , 419            P                                            T       HO
                                             HO                                                             O
                            phosphoSer                O       H                             420 , 422 HO P                 H
                                                                                           phosphoThr       H
                                                                                                          O
                                                      H2 N    CO2H                                          H2N                CO2H




64
WHO Drug Information, Vol. 29, No. 1, 2015                             Recommended INN: List 73




 asvasiranum
 asvasiran                             small interfering ARN (siRNA) inhibitor of human
                                       Respiratory Syncytial Virus replication;
                                       duplex of guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-
                                       (3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-
                                       uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-
                                       (3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-
                                       guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-
                                       (3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-
                                       (3'→5')-thymidine and thymidylyl-(5'→3')-thymidylyl-
                                       (5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-
                                       adenylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-
                                       adenylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-
                                       (5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-
                                       cytidylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
                                       (5'→3')-uridylyl-(5'→3')-cytidine

 asvasiran                             petit ARN interférant (siRNA) inhibiteur de la réplication du
                                       virus respiratoire syncytial humain;
                                       duplex de guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-
                                       (3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-
                                       uridylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-
                                       (3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-
                                       guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-
                                       (3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-
                                       (3'→5')-thymidine et de thymidylyl-(5'→3')-thymidylyl-
                                       (5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-
                                       adénylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-
                                       adénylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-
                                       (5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-
                                       cytidylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
                                       (5'→3')-uridylyl-(5'→3')-cytidine

 asvasirán                             ARN pequeño de interferencia (ARNip) (siRNA) inhibidor
                                       de la replicación del virus respiratorio sincitial humano;
                                       duplex de guanilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-
                                       uridilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-
                                       adenilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-
                                       (3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-
                                       uridilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-
                                       (3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-timidina y de
                                       timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-citidilil-
                                       (5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-
                                       adenilil-(5'→3')-adenilil-(5'→3')-uridilil-(5'→3')-citidilil-
                                       (5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-uridilil-
                                       (5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-
                                       uridilil-(5'→3')-uridilil-(5'→3')-citidina

                                       C401H500N150O290P40

                                              [(3’-5’)-G-G-C-U-C-U-U-A-G-C-A-A-A-G-U-C-A-A-G-dT-dT]
                                                       . . . . . . . . . . . . . . . . . . .
                                       [(5’-3’)-dT-dT-C-C-G-A-G-A-A-U-C-G-U-U-U-C-A-G-U-U-C]




                                                                                                         65
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015


 azeliragonum
 azeliragon                3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-
                           4-yl}phenoxy)-N,N-diethylpropan-1-amine

 azéliragon                3-(4-{2-butyl-1-[4-(4-chlorophénoxy)phényl]-1H-imidazol-
                           4-yl}phénoxy)-N,N-diéthylpropan-1-amine

 azeliragón                3-(4-{2-butil-1-[4-(4-clorofenoxi)fenil]-1H-imidazol-
                           4-il}fenoxi)-N,N-dietilpropan-1-amina

                           C32H38ClN3O2

                                                            N
                                          H3C
                                                                                O
                            Cl                          N                               CH3
                                                                                    N
                                            O                                           CH3



 basmisanilum
                                            6
 basmisanil                (1,1-dioxo-1λ -thiomorpholin-4-yl)(6-{[3-(4-fluorophenyl)-
                           5-methyl-1,2-oxazol-4-yl]methoxy}pyridin-3-yl)methanone
                                            6
 basmisanil                (1,1-dioxo-1λ -thiomorpholin-4-yl)(6-{[3-(4-fluorophényl)-
                           5-méthyl-1,2-oxazol-4-yl]méthoxy}pyridin-3-yl)méthanone
                                            6
 basmisanil                (1,1-dioxo-1λ -tiomorfolin-4-il)(6-{[3-(4-fluorofenil)-5-metil-
                           1,2-oxazol-4-il]metoxi}piridin-3-il)metanona

                           C21H20FN3O5S

                             F

                                                            O

                                                    N           N
                                                                    S       O
                                                O
                                 N                                      O
                                     O
                                          CH3



 beclabuvirum
 beclabuvir                (4bS,5aR)-12-cyclohexyl-N-(dimethylsulfamoyl)-
                           3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-
                           8-yl)carbonyl]-4b,5,5a,6-tetrahydrocyclopropa[d]indolo[2,1-
                           a][2]benzazepine-9-carboxamide

 béclabuvir                (4bS,5aR)-12-cyclohexyl-N-(diméthylsulfamoyl)-
                           3-méthoxy-5a-[(3-méthyl-3,8-diazabicyclo[3.2.1]oct-
                           8-yl)carbonyl]-4b,5,5a,6-tétrahydrocyclopropa[d]indolo[2,1-
                           a][2]benzazépine-9-carboxamide

 beclabuvir                (4bS,5aR)-12-ciclohexil-N-(dimetilsulfamoil)-3-metoxi-
                           5a-[(3-metil-3,8-diazabiciclo[3.2.1]oct-8-il)carbonil]-
                           4b,5,5a,6-tetrahidrociclopropa[d]indolo[2,1-
                           a][2]benzazepina-9-carboxamida




66
WHO Drug Information, Vol. 29, No. 1, 2015                         Recommended INN: List 73


                                       C36H45N5O5S

                                                       O
                                                            N      N CH3
                                                                       O   O O
                                                H
                                                           N                   S       CH3
                                                                           N       N
                                                                           H
                                        H3CO                                       CH3




 begelomabum #
 begelomab                             immunoglobulin G2b-kappa, anti-[Homo sapiens
                                       DPP4(dipeptidyl-peptidase 4, dipeptidylpeptidase IV,
                                       adenosine deaminase complexing protein 2, ADCP2,
                                       TP103, T cell activation antigen CD26, CD26)], Mus
                                       musculus monoclonal antibody;
                                       gamma2b heavy chain (1-456) [Mus musculus VH (IGHV1-
                                       85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -
                                       IGHG2B*02 (CH1 (121-217), hinge (218-239), CH2 (240-
                                       349), CH3 (350-454), CHS (455-456)) (121-456)], (135-
                                       213')-disulfide with kappa light chain (1'-213') [Mus
                                       musculus V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01)
                                       [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimer (229-
                                       229'':232-232'':235-235'':238-238'')-tetrakisdisulfide

 bégélomab                             immunoglobuline G2b-kappa, anti-[Homo sapiens DPP4
                                       (dipeptidyl-peptidase 4, dipeptidylpeptidase IV, protéine 2
                                       complexant l’adénosine désaminase, ADCP2, TP103,
                                       antigène CD26 d’activation des cellules T, CD26)], Mus
                                       musculus anticorps monoclonal;
                                       chaîne lourde gamma2b (1-456) [Mus musculus VH
                                       (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-
                                       120) -IGHG2B*02 (CH1 (121-217), charnière (218-239),
                                       CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-
                                       456)], (135-213')-disulfure avec la chaîne légère kappa (1'-
                                       213') [Mus musculusV-KAPPA (IGKV4-57*01 (98.90%) -
                                       IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimère
                                       (229-229'':232-232'':235-235'':238-238'')-tétrakisdisulfure

 begelomab                             inmunoglobulina G2b-kappa, anti-[Homo sapiens DPP4
                                       (dipeptidil-peptidasa 4, dipeptidilpeptidasa IV, proteína 2
                                       complejante de la adenosina desaminasa, ADCP2, TP103,
                                       antígeno CD26 de activación de las células T, CD26)],
                                       anticuerpo monoclonal de Mus musculus ;
                                       cadena pesada gamma2b (1-456) [Mus musculus VH
                                       (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-
                                       120) -IGHG2B*02 (CH1 (121-217), bisagra (218-239), CH2
                                       (240-349), CH3 (350-454), CHS (455-456)) (121-456)],
                                       (135-213')-disulfuro con la cadena ligera kappa (1'-213')
                                       [Mus musculus V-KAPPA (IGKV4-57*01 (98.90%) -
                                       IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dímero
                                       (229-229'':232-232'':235-235'':238-238'')-tetrakisdisulfuro




                                                                                                 67
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGAE LVKPGASVKL SCKASGYTFR                  SYDINWVRQR       PEQGLEWIGW        50
                           IFPGDGSTKY NEKFKGKATL TTDKSSSTAY                  MQLSRLTSED       SAVYFCARWT       100
                           VVGPGYFDVW GAGTTVTVSS AKTTPPSVYP                  LAPGCGDTTG       SSVTLGCLVK       150
                           GYFPESVTVT WNSGSLSSSV HTFPALLQSG                  LYTMSSSVTV       PSSTWPSQTV       200
                           TCSVAHPASS TTVDKKLEPS GPISTINPCP                  PCKECHKCPA       PNLEGGPSVF       250
                           IFPPNIKDVL MISLTPKVTC VVVDVSEDDP                  DVQISWFVNN       VEVHTAQTQT       300
                           HREDYNSTIR VVSTLPIQHQ DWMSGKEFKC                  KVNNKDLPSP       IERTISKIKG       350
                           LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG                  FNPGDISVEW       TSNGHTEENY       400
                           KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD                  SFSCNVRHEG       LKNYYLKKTI       450
                           SRSPGK                                                                              456

                           Light chain / Chaîne légère / Cadena ligera
                           QIVLTQSPAI MSASPGEKVT ITCSASSSVS                  YMNWFQQKPG       TSPKLWIYST 50
                           SNLASGVPAR FSGSGSGTSY SLTISRMEAE                  DAATYYCQQR       SSYPNTFGGG 100
                           TKLEIKRADA APTVSIFPPS SEQLTSGGAS                  VVCFLNNFYP       KDINVKWKID 150
                           GSERQNGVLN SWTDQDSKDS TYSMSSTLTL                  TKDEYERHNS       YTCEATHKTS 200
                           TSPIVKSFNR NEC                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          147-202       270-330   376-434
                                                 22''-96'' 147''-202'' 270''-330'' 376''-434''
                           Intra-L (C23-C104) 23'-87' 133'-193'
                                                 23'''-87''' 133'''-193'''
                           Inter-H-L (CH1 11-CL 126)             135-213' 135''-213'''
                           Inter-H-H (h 12, h 15, h 18, h 21) 229-229'' 232-232'' 235-235'' 238-238''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           306, 306''



 benzhydrocodonum
 benzhydrocodone           4,5α-epoxy-3-methoxy-17-methyl-6,7-didehydromorphinan-
                           6-yl benzoate

 benzhydrocodone           benzoate de 4,5α-époxy-3-méthoxy-17-méthyl-
                           6,7-didéhydromorphinan-6-yle

 benzhidrocodona           benzoato de 4,5α-epoxi-17-metil-3-metoxi-
                           6,7-dideshidromorfinan-6-ilo

                           C25H25NO4

                                                         CH3
                                              H     N

                                               H



                            H3CO               O            O
                                                    H
                                                                    O



 bradaniclinum
 bradanicline              N-[(2S,3R)-2-[(pyridin-3-yl)methyl]-1-azabicyclo[2.2.2]oct-
                           3-yl]-1-benzofuran-2-carboxamide

 bradanicline              N-[(2S,3R)-2-(pyridin-3-ylméthyl)-1-azabicyclo[2.2.2]oct-
                           3-yl]-1-benzofurane-2-carboxamide

 bradaniclina              N-[(2S,3R)-2-(piridin-3-ilmetil)-1-azabiciclo[2.2.2]oct-3-il]-
                           1-benzofurano-2-carboxamida




68
WHO Drug Information, Vol. 29, No. 1, 2015                             Recommended INN: List 73


                                       C22H23N3O2

                                                       N


                                                 H
                                             N
                                                       O

                                                   N
                                                 H H
                                                           O



 briciclibum
 briciclib                             2-methoxy-5-({[(E)-2-(2,4,6-
                                       trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl
                                       dihydrogen phosphate

 briciclib                             dihydrogénophosphate de 2-méthoxy-5-({[2-(2,4,6-
                                       triméthoxyphényl)éthényl]sulfonyl}méthyl)phenyl

 briciclib                             dihidrógenofosfato de 2-metoxi-5-({[2-(2,4,6-
                                       trimetoxifenil)etenil]sulfonil}metil)fenilo

                                       C19H23O10PS

                                                                                   OH
                                        H3CO                OCH3           O
                                                                               P    OH
                                                                               O
                                                                   S
                                                     OCH3      O O
                                                                               OCH3

 brontictuzumabum #
 brontictuzumab                        immunoglobulin G2-lambda, anti-[Homo sapiens NOTCH1
                                       (Notch 1, Translocation-associated notch-1, TAN-
                                       1,TAN1)], humanized monoclonal antibody;
                                       gamma2 heavy chain (1-447) [humanized VH (Homo
                                       sapiens IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T
                                       (116)) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1
                                       (122-219), hinge (220-231), CH2 (232-340), CH3 (341-
                                       445), CHS (446-447)) (122-447)],(135-214')-disulfide with
                                       lambda light chain (1'-215’) [humanized V-LAMBDA (Homo
                                       sapiens IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9] (1'-109')
                                       -Homo sapiens IGLC7*01 (110'-215')]; dimer (223-
                                       223'':224-224'':227-227'':230-230'')-tetrakisdisulfide

 brontictuzumab                        immunoglobuline G2-lambda, anti-[Homo sapiens
                                       NOTCH1 (Notch 1, notch-1 associé aux translocations,
                                       TAN-1,TAN1)], anticorps monoclonal humanisé;
                                       chaîne lourde gamma2 (1-447) [VH humanisé (Homo
                                       sapiens IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T
                                       (116)) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1
                                       (122-219), charnière (220-231), CH2 (232-340), CH3 (341-
                                       445), CHS (446-447)) (122-447)], (135-214')-disulfure avec
                                       la chaîne légère lambda (1'-215') [V-LAMBDA humanisé
                                       (Homo sapiens IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9]
                                       (1'-109') -Homo sapiens IGLC7*01 (110'-215')]; dimère
                                       (223-223'':224-224'':227-227'':230-230'')-tétrakisdisulfure



                                                                                               69
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




 brontictuzumab            inmunoglobulina G2-lambda, anti-[NOTCH1 de Homo
                           sapiens (Notch 1, notch-1 asociado a las translocaciones,
                           TAN-1,TAN1)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma2 (1-447) [VH humanizado (Homo
                           sapiens IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T
                           (116)) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1
                           (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-
                           445), CHS (446-447)) (122-447)], (135-214')-disulfuro con
                           la cadena ligera lambda (1'-215') [V-LAMBDA humanizada
                           (Homo sapiens IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9]
                           (1'-109') -Homo sapiens IGLC7*01 (110'-215')]; dímero
                           (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKI SCKVSGYTLR                  GYWIEWVRQA       PGKGLEWIGQ        50
                           ILPGTGRTNY NEKFKGRVTM TADTSTDTAY                  MELSSLRSED       TAVYYCARFD       100
                           GNYGYYAMDY WGQGTTVTVS SASTKGPSVF                  PLAPCSRSTS       ESTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSNFGTQ       200
                           TYTCNVDHKP SNTKVDKTVE RKCCVECPPC                  PAPPVAGPSV       FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVQFNWYVD                  GVEVHNAKTK       PREEQFNSTF       300
                           RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA                  PIEKTISKTK       GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPMLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           QAVVTQEPSL TVSPGGTVTL TCRSSTGAVT                  TSNYANWFQQ       KPGQAPRTLI 50
                           GGTNNRAPGV PARFSGSLLG GKAALTLSGA                  QPEDEAEYYC       ALWYSNHWVF 100
                           GGGTKLTVLG QPKAAPSVTL FPPSSEELQA                  NKATLVCLVS       DFYPGAVTVA 150
                           WKADGSPVKV GVETTKPSKQ SNNKYAASSY                  LSLTPEQWKS       HRSYSCRVTH 200
                           EGSTVEKTVA PAECS                                                              215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96           148-204       261-321  367-425
                                                  22''-96'' 148''-204'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 22'-90'          137'-196'
                                                  22'''-90''' 137'''-196'''
                           Inter-H-L (CH1 10-CL 126) 135-214' 135''-214'''
                           Inter-H-H (h 4, h 5, h 8, h 11) 223-223'' 224-224'' 227-227'' 230-230''
                           Possible other H-L and H-H crosslinks
                           Inter-H-L 223-214' 223''-214'''
                           Inter-H-H 135-224'' 135''-224 227-227'' 230-230''
                           Possible other H-L and H-H crosslinks
                           Inter-H-L 135-214' 223''-214'''
                           Inter-H-H 223-135'' 224-224'' 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''


 butylphthalidum
 butylphthalide            rac-3-butyl-2-benzofuran-1(3H)-one

 butylphthalide            rac-3-butyl-2-benzofuran-1(3H)-one

 butilftalida              rac-3-butil-2-benzofuran-1(3H)-ona

                           C12H14O2

                                            O
                                                                    and enantiomer
                                            O                       et énantiomère
                                                                    y enantiómero

                                        H                  CH3


 cabotegravirum
 cabotegravir              (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-
                           3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-
                           a]pyrido[1,2-d]pyrazine-8-carboxamide




70
WHO Drug Information, Vol. 29, No. 1, 2015                                Recommended INN: List 73




 cabotégravir                          (3S,11aR)-N-[(2,4-difluorophényl)méthyl]-6-hydroxy-
                                       3-méthyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-
                                       a]pyrido[1,2-d]pyrazine-8-carboxamide

 cabotegravir                          (3S,11aR)-N-[(2,4-difluorofenil)metil]-6-hidroxi-3-metil-
                                       5,7-dioxo-2,3,5,7,11,11a-hexahidrooxazolo[3,2-
                                       a]pirido[1,2-d]pirazina-8-carboxamida

                                       C19H17F2N3O5

                                             CH3 O       OH
                                        H
                                                                  O       F         F
                                                 N
                                                                      H
                                                     N                N
                                             O
                                                 H
                                                                  O



 capmatinibum
 capmatinib                            2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-
                                       b][1,2,4]triazin-2-yl}benzamide

 capmatinib                            2-fluoro-N-méthyl-4-{7-[(quinoléin-6-yl)méthyl]imidazo[1,2-
                                       b][1,2,4]triazin-2-yl}benzamide

 capmatinib                            2-fluoro-N-metil-4-{7-[(quinolein-6-il)metil]imidazo[1,2-
                                       b][1,2,4]triazin-2-il}benzamida

                                       C23H17FN6O


                                                                                O
                                        N                                               CH3
                                                                                    N
                                                                                    H
                                                                  N
                                                              N                 F

                                                         N        N



 cefilavancinum
 cefilavancin                          (6R,7R)-7-[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-({3-
                                       [(3S,6R,7R,22R,23S,26S,30aSa,36R,38aR)-3-(2-amino-
                                       2-oxoethyl)-44-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-
                                       α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}-
                                       10,19-dichloro-7,22,28,30,32-pentahydroxy-6-[(N-methyl-
                                       D-leucyl)amino]-2,5,24,38,39-pentaoxo-
                                       2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-
                                       1H,22H-8,11:18,21-dietheno-23,36-(iminomethano)-
                                       13,16:31,35-dimetheno[1,6,9]oxadiazacyclohexadecino
                                       [4,5-m][10,2,16]benzoxadiazacyclotetracosine-
                                       26-carboxamido]propoxy}imino)acetamido]-8-oxo-
                                       3-[(pyridin-1-ium-1-yl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-
                                       2-ene-2-carboxylate




                                                                                                    71
Recommended INN: List 73               WHO Drug Information, Vol. 29, No. 1, 2015



 céfilavancine             (6R,7R)-7-[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-({3-
                           [(3S,6R,7R,22R,23S,26S,30aSa,36R,38aR)-3-(2-amino-
                           2-oxoéthyl)-44-{[2-O-(3-amino-2,3,6-tridéoxy-3-C-méthyl-
                           α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}-
                           10,19-dichloro-7,22,28,30,32-pentahydroxy-6-[(N-méthyl-
                           D-leucyl)amino]-2,5,24,38,39-pentaoxo-
                           2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-
                           1H,22H-8,11:18,21-diéthéno-23,36-(iminométhano)-
                           13,16:31,35-diméthéno[1,6,9]oxadiazacyclohexadécino
                           [4,5-m][10,2,16]benzoxadiazacyclotétracosine-
                           26-carboxamido]propoxy}imino)acétamido]-8-oxo-
                           3-[(pyridin-1-ium-1-yl)méthyl]-5-thia-1-azabicyclo[4.2.0]oct-
                           2-ène-2-carboxylate

 cefilavancina             (6R,7R)-7-[(2Z)-2-(2-amino-5-cloro-1,3-tiazol-4-il)-2-({3-
                           [(3S,6R,7R,22R,23S,26S,30aSa,36R,38aR)-3-(2-amino-
                           2-oxoetil)-44-{[2-O-(3-amino-2,3,6-tridesoxi-3-C-metil-
                           α-L-lixo-hexopiranosil)-β-D-glucopiranosil]oxi}-
                           10,19-dicloro-7,22,28,30,32-pentahidroxi-6-[(N-metil-
                           D-leucil)amino]-2,5,24,38,39-pentaoxo-
                           2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahidro-
                           1H,22H-8,11:18,21-dieteno-23,36-(iminometano)-
                           13,16:31,35-dimeteno[1,6,9]oxadiazaciclohexadecino
                           [4,5-m][10,2,16]benzoxadiazaciclotetracosina-
                           26-carboxamido]propoxi}imino)acetamido]-8-oxo-
                           3-[(piridin-1-io-1-il)metil]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-
                           2-carboxilato

                           C87H95Cl3N16O28S2
                                                                                  H3C       NH
                                                                                                              CH3
                                                                                        H
                                                                                                         CH3
                                                                                       HN            O
                                                                                   H
                                                                              O                      H
                                                                 H2N
                                                                                                         OH
                                                                                   NH
                                                                     O H
                                                                                                            H3C         NH2
                                                                         HN        O                      Cl                  OH
                                        HO                           H
                                       OH                        O                               O
                                                                 H                                        O         O         CH3
                                                                     NH
                                                                                                 O                  OH
                                                     H
                              HO                         HN          O              O
                                   O                                                                 O
                                                     H                                                              OH
                                             HN
                                       HN                                           Cl
                                                                                                 HO
                                                     O       HO H
                                                                     CO2
                                                 O       O
                                            N                    N                 N
                                                     H
                                   N                 N
                                                                     S
                            H2N                              H   H
                                                 O
                                   S        Cl



 cerdulatinibum
 cerdulatinib              4-(cyclopropylamino)-2-({4-[4-(ethanesulfonyl)piperazin-
                           1-yl]phenyl}amino)pyrimidine-5-carboxamide




72
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73


 cerdulatinib                          4-(cyclopropylamino)-2-({4-[4-(éthanesulfonyl)pipérazin-
                                       1-yl]phényl}amino)pyrimidine-5-carboxamide

 cerdulatinib                          4-(ciclopropilamino)-2-({4-[4-(etanosulfonil)piperazin-
                                       1-il]fenil}amino)pirimidina-5-carboxamida

                                       C20H27N7O3S
                                                                                                O O
                                                                                                 S           CH3
                                                O                                              N
                                                                                      N
                                        H2N                   N

                                              HN         N         N
                                                                   H



 cerliponasum alfa #
 cerliponase alfa                      immature human tripeptidyl-peptidase 1 (cell growth-
                                       inhibiting gene 1 protein, lysosomal pepstatin-insensitive
                                       protease, TPP-1, EC 3.4.14.9), 544 residues protein,
                                       produced in Chinese hamster ovary (CHO) cells, glycoform
                                       alfa

 cerliponase alfa                      tripeptidyl-peptidase 1 humaine immature (protéine du
                                       gène 1 inhibitrice du développement cellulaire, protéase
                                       lysosomiale non-contrôlée par la pepstatine, TPP-1, EC
                                       3.4.14.9), protéine de 544 résidus, produite par des
                                       cellules ovariennes de hamster chinois, forme glycosylée
                                       alfa

 cerliponasa alfa                      tripeptidil-peptidasa 1 humana inmadura (proteína del gen
                                       1 inhibidora del desarrollo celular, proteasa lisosomial no
                                       controlada por la pepstatina, TPP-1, EC 3.4.14.9), proteína
                                       de 544 restos, producida por células ováricas de hamster
                                       chino, forma glicosilada alfa

                                       C2657H4042N734O793S11
                                       Sequence / Séquence / Secuencia
                                       SYSPEPDQRR TLPPGWVSLG RADPEEELSL                   TFALRQQNVE      RLSELVQAVS       50
                                       DPSSPQYGKY LTLENVADLV RPSPLTLHTV                   QKWLLAAGAQ      KCHSVITQDF       100
                                       LTCWLSIRQA ELLLPGAEFH HYVGGPTETH                   VVRSPHPYQL      PQALAPHVDF       150
                                       VGGLHRFPPT SSLRQRPEPQ VTGTVGLHLG                   VTPSVIRKRY      NLTSQDVGSG       200
                                       TSNNSQACAQ FLEQYFHDSD LAQFMRLFGG                   NFAHQASVAR      VVGQQGRGRA       250
                                       GIEASLDVQY LMSAGANIST WVYSSPGRHE                   GQEPFLQWLM      LLSNESALPH       300
                                       VHTVSYGDDE DSLSSAYIQR VNTELMKAAA                   RGLTLLFASG      DSGAGCWSVS       350
                                       GRHQFRPTFP ASSPYVTTVG GTSFQEPFLI                   TNEIVDYISG      GGFSNVFPRP       400
                                       SYQEEAVTKF LSSSPHLPPS SYFNASGRAY                   PDVAALSDGY      WVVSNRVPIP       450
                                       WVSGTSASTP VFGGILSLIN EHRILSGRPP                   LGFLNPRLYQ      QHGAGLFDVT       500
                                       RGCHESCLDE EVEGQGFCSG PGWDPVTGWG                   TPNFPALLKT      LLNP             544

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       92-103 346-507 503-518

                                       Glycosylation sites (N)/ Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                       Asn-191 Asn-203 Asn-267 Asn-294 Asn-424


 dagrocoratum
 dagrocorat                            (4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-methylpyridin-
                                       3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8a,9,10-
                                       octahydrophenanthrene-2-carboxamide

 dagrocorat                            (4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-méthylpyridin-
                                       3-yl)-7-(trifluorométhyl)-4b,5,6,7,8,8a,9,10-
                                       octahydrophénanthrène-2-carboxamide



                                                                                                                                  73
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015



 dagrocorat                (4bS,7R,8aR)-4b-bencil-7-hidroxi-N-(2-metilpiridin-3-il)-
                           7-(trifluorometil)-4b,5,6,7,8,8a,9,10-octahidrofenantreno-
                           2-carboxamida

                           C29H29F3N2O2


                                                                               OH
                                                                                 CF3

                                   CH3
                                          H                                H
                                          N
                            N
                                              O


 dalazatidum
 dalazatide                a 37-residue, synthetic peptide derivative of the
                           Stichodactyla toxin:
                           O-phosphono-L-tyrosyl-2-[2-(2-
                           aminoethoxy)ethoxy]acetyl[potassium channel toxin kappa-
                           stichotoxin-Shela Stoichactis helianthus (Caribbean sea
                           anemone)] peptidamide

 dalazatide                peptide sythétique de 37 acides aminés dérivé de la toxine
                           extraite de Stichodactyla:
                           O-phosphono-L-tyrosyl-2-[2-(2-
                           aminoéthoxy)éthoxy]acétyl[toxine kappa du canal
                           potassique-stichotoxine-Shela Stoichactis helianthus
                           (anémone de mer des Antilles)] peptidamide

 dalazatida                péptido sintético de 37 aminoácidos derivado de la toxina
                           extraída de Stichodactyla:
                           O-fosfono-L-tirosil-2-[2-(2-aminoetoxi)etoxi]acetil[toxina
                           kappa del canal de potasio-stichotoxina-Shela Stoichactis
                           helianthus (anémona del Mar de las Antillas)] peptidamida

                           C184H296N57O55PS7
                           Sequence / Séquence / Secuencia
                           YXRSCIDTIP KSRCTAFQCK HSMKYRLSFC RKTCGTC                           37

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           5-37 14-30 19-34

                           Modified residues / Résidus modifiés / Restos modificados
                           X (2) 2-[2-(2-aminoethoxy)ethoxy]acetic acid          H2N                    O       CO2H
                                          HO     O                                           O
                                  Y                                                     C      HS           H
                                  1           P                H NH2
                                                                                       37                       NH2
                            O-phosphonoTyr O OH                                   cysteinamide  H2N
                                                                      CO2H
                                                                                                            O


 dapaconazolum
 dapaconazole              1-[rac-2-(2,4-dichlorophenyl)-
                           2-{[4-(trifluoromethyl)phenyl]methoxy}ethyl]-1H-imidazole

 dapaconazole              1-[rac-2-(2,4-dichlorophényl)-
                           2-{[4-(trifluorométhyl)phényl]méthoxy}éthyl]-1H-imidazole

 dapaconazol               1-[rac-2-(2,4-diclorofenil)-
                           2-{[4-(trifluorometil)fenil]metoxi}etil]-1H-imidazol




74
WHO Drug Information, Vol. 29, No. 1, 2015                                       Recommended INN: List 73


                                       C19H15Cl2F3N2O

                                                                                 Cl

                                                            Cl
                                                                 H                    and enantiomer
                                                                                      et énantiomère
                                                               O                      y enantiómero
                                                                         N
                                        F3C
                                                                             N

 defactinibum
 defactinib                            N-methyl-4-({4-({[3-(N-methylmethanesulfonamido)pyrazin-
                                       2-yl]methyl}amino)-5-(trifluoromethyl)pyrimidin-
                                       2-yl}amino)benzamide

 défactinib                            N-méthyl-4-({4-({[3-(N-méthylméthanesulfonamido)pyrazin-
                                       2-yl]méthyl}amino)-5-(trifluorométhyl)pyrimidin-
                                       2-yl}amino)benzamide

 defactinib                            N-metil-4-({4-({[3-(N-metilmetanesulfonamido)pirazin-
                                       2-il]metil}amino)-5-(trifluorometil)pirimidin-
                                       2-il}amino)benzamida

                                       C20H21F3N8O3S

                                                                                       O
                                                 F3C                                           CH3
                                                               N                           N
                                                                                           H
                                                 HN        N         N
                                                                     H
                                             N
                                                    O O
                                                     S
                                             N     N   CH3
                                                   CH3



 denintuzumabum mafodotinum #
 denintuzumab mafodotin                immunoglobulin G1-kappa auristatin F conjugate, anti-
                                       [Homo sapiens CD19 (B lymphocyte surface antigen B4,
                                       Leu-12)], humanized monoclonal antibody;
                                       gamma1 heavy chain (1-450) [humanized VH (Homo
                                       sapiens IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01)
                                       [10.7.12] (1-120) -Homo sapiens IGHG1*01 (CH1 (121-
                                       218), hinge (219-233), CH2 (234-343), CH3 (344-448),
                                       CHS (449-450)) (121-450)], (223-213')-disulfide with kappa
                                       light chain (1’-213’) [humanized V-KAPPA (Homo sapiens
                                       IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -Homo
                                       sapiens IGKC*01 (107'-213')]; dimer (229-229":232-232")-
                                       bisdisulfide; conjugated, on an average of 4 cysteinyl, to
                                       monomethylauristatin F (MMAF), via a noncleavable
                                       maleimidocaproyl (mc) linker
                                       For the mafodotin part, please refer to the document "INN for pharmaceutical
                                       substances: Names for radicals, groups and others"*.




                                                                                                                  75
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015




 dénintuzumab mafodotine   immunoglobuline G1-kappa conjuguée à l’auristatine F,
                           anti-[Homo sapiens CD19 (antigène de surface B4 des
                           lymphocytes B, Leu-12)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-450) [VH humanisé (Homo
                           sapiens IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01)
                           [10.7.12] (1-120) -Homo sapiens IGHG1*01 (CH1 (121-
                           218), charnière (219-233), CH2 (234-343), CH3 (344-448),
                           CHS (449-450)) (121-450)], (223-213')-disulfure avec la
                           chaîne légère kappa (1’-213’) [V-KAPPA humanisé (Homo
                           sapiens IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106')
                           -Homo sapiens IGKC*01 (107'-213')]; dimère (229-
                           229":232-232")-bisdisulfure; conjugué, sur 4 cystéinyl en
                           moyenne, au monométhylauristatine F (MMAF), via un
                           linker maléimidocaproyl (mc) non clivable
                           Pour la partie mafodotine, veuillez-vous référer au document "INN for
                           pharmaceutical substances: Names for radicals, groups and others"*.


 denintuzumab mafodotina   inmunoglobulina G1-kappa conjugada con la auristatina F,
                           anti-[CD19 de Homo sapiens (antígeno de superficie B4 de
                           los linfocitos B, Leu-12)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma1 (1-450) [VH humanizado (Homo
                           sapiens IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01)
                           [10.7.12] (1-120) -Homo sapiens IGHG1*01 (CH1 (121-
                           218), bisagra (219-233), CH2 (234-343), CH3 (344-448),
                           CHS (449-450)) (121-450)], (223-213')-disulfuro con la
                           cadena ligera kappa (1’-213’) [V-KAPPA humanizado
                           (Homo sapiens IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9]
                           (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dímero
                           (229-229":232-232")-bisdisulfuro; conjugado, en 4 restos
                           cisteinil por término medio, con monometilauristatina F
                           (MMAF), mediante un conector maleimidocaproil (mc) no
                           escindible
                           La fracción mafodotina, pueden encontrarla en el documento "INN for
                           pharmaceutical substances: Names for radicals, groups and others"*.



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQESGPG LVKPSQTLSL TCTVSGGSIS                  TSGMGVGWIR       QHPGKGLEWI        50
                           GHIWWDDDKR YNPALKSRVT ISVDTSKNQF                  SLKLSSVTAA       DTAVYYCARM       100
                           ELWSYYFDYW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAT LSCSASSSVS                  YMHWYQQKPG       QAPRLLIYDT 50
                           SKLASGIPAR FSGSGSGTDF TLTISSLEPE                  DVAVYYCFQG       SVYPFTFGQG 100
                           TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                           SSPVTKSFNR GEC                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-97         147-203       264-324    370-428
                                                 22''-97'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 23'-87' 133'-193'
                                                23'''-87''' 133'''-193'''
                           Inter-H-L (h 5-CL 126) * 223-213' 223''-213'''
                           Inter-H-H (h 11, h 14) * 229-229'' 232-232''

                           *Two inter-chain disulfide bridges are not present on average, the antibody being conjugated
                           to an average of 4 drug linkers, each bound to a cysteinyl via a thioether bond
                           *Deux des ponts disulfure inter-chaines ne sont pas présents en moyenne, l'anticorps étant
                           conjugué à une moyenne de 4 linker-principe actif, chacun via une liaison thioéther.
                           * Faltan dos puentes disulfuro intercatenarios por estar el anticuerpo conjugado, con sendos
                           enlaces tioéter, a una media de 4 conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''




76
WHO Drug Information, Vol. 29, No. 1, 2015                                                            Recommended INN: List 73




 dianhydrogalactitolum
 dianhydrogalactitol                   meso-(1R,2S)-1-[(2R)-oxiran-2-yl]-2-[(2S)-oxiran-
                                       2-yl]ethane-1,2-diol

 dianhydrogalactitol                   méso-(1R,2S)-1-[(2R)-oxiran-2-yl]-2-[(2S)-oxiran-
                                       2-yl]éthane-1,2-diol

 dianhidrogalactitol                   meso-(1R,2S)-1-[(2R)-oxiran-2-il]-2-[(2S)-oxiran-2-il]etano-
                                       1,2-diol

                                       C6H10O4

                                                 H OH
                                            H                                  O

                                        O                                  H
                                                     HO H



 diclofenaci etalhyaluronas
 diclofenac etalhyaluronate            hyaluronic acid partly amidified with 2-(2-{2-[(2,6-
                                       dichlorophenyl)amino]phenyl}acetyloxy)ethanamine

 étalhyaluronate de diclofénac         acide hyaluronique partiellement amidifié par la 2-(2-{2-
                                       [(2,6-dichlorophényl)amino]phényl}acétyloxy)éthanamine

 etalhialuronato de diclofenaco        ácido hialurónico parcialmente amidificado por 2-(2-{2-
                                       [(2,6-diclorofenil)amino]fenil}acetiloxi)etanamina

                                       [(C30H35Cl2N3O12)a(C14H21NO11)b]nH2O


                                                                       Cl

                                                 Cl           HN
                                                              O
                                                                                                              OH
                                                              O                                                             HO2C
                                                                                    O                              O                 O
                                                HO                     HN                            HO                     O                     OH
                                                                  O                     O
                                                HO                         O                              O            NH       HO       OH
                                                                                                              O
                                        H             O               NH       HO           OH                         CH3
                                                                                                                                              b
                                                          O
                                                                      CH3
                                                                                                 a                                                n




 diridavumabum #
 diridavumab                           immunoglobulin G1-lambda2, anti-[influenza A virus
                                       hemagglutinin HA2 subunit (H1, H2, H5, H6, H8 and H9
                                       subtypes)], Homo sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV1-
                                       69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14](1-121) -
                                       IGHG1*03 (CH1 (122-219), hinge (220-234), CH2 (235-
                                       344), CH3 (345-449), CHS K2>del (450)(122-450)],(224-
                                       216')-disulfide with lambda2 light chain(1'-217') [Homo
                                       sapiens V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01)
                                       [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (230-
                                       230'':233-233'')-bisdisulfide




                                                                                                                                                       77
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015


 diridavumab               immunoglobuline G1-lambda2, anti-[sous-unité HA2 de
                           l'hémagglutinine du virus de la grippe A (sous-types H1,
                           H2, H5, H6, H8 et H9)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma1 (1-450) [Homo sapiens VH
                           (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14](1-
                           121) -IGHG1*03 (CH1 (122-219), charnière (220-234),
                           CH2 (235-344), CH3 (345-449), CHS K2>del (450)(122-
                           450)],(224-216')-disulfure avec la chaîne légère lambda2
                           (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01
                           (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-
                           217')]; dimère (230-230'':233-233'')-bisdisulfure

 diridavumab               inmunoglobulina G1-lambda2, anti-[subunidad HA2 de la
                           hemaglutinina del virus de la gripe A (sub-tipos H1, H2,
                           H5, H6, H8 y H9)], anticuerpo monoclonal de Homo
                           sapiens ;
                           cadena pesada gamma1 (1-450) [Homo sapiens VH
                           (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14] (1-
                           121) -IGHG1*03 (CH1 (122-219), bisagra (220-234), CH2
                           (235-344), CH3 (345-449), CHS K2>del (450) (122-450)],
                           (224-216')-disulfuro con la cadena ligera lambda2 (1'-217')
                           [Homo sapiens V-LAMBDA (IGLV1-51*01 (92.90%) -
                           IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero
                           (230-230'':233-233'')-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGAE VKKPGSSVKV SCKASGGPFR                  SYAISWVRQA       PGQGPEWMGG        50
                           IIPIFGTTKY APKFQGRVTI TADDFAGTVY                  MELSSLRSED       TAMYYCAKHM       100
                           GYQVRETMDV WGKGTTVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450

                           Light chain / Chaîne légère / Cadena ligera
                           QSVLTQPPSV SAAPGQKVTI SCSGSSSNIG                  NDYVSWYQQL       PGTAPKLLIY 50
                           DNNKRPSGIP DRFSGSKSGT SATLGITGLQ                  TGDEANYYCA       TWDRRPTAYV 100
                           VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                           VAWKADSSPV KAGVETTTPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                            217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          148-204       265-325   371-429
                                                 22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L (C23-C104) 22'-89'         139'-198'
                                                 22'''-89''' 139'''-198'''
                           Inter-H-L (h 5-CL 126) 224-216' 224''-216'''
                           Inter-H-H (h 11, h 14) 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           301, 301''

                           Other post-translational modifications
                           Autres modifications post-traductionnelles
                           Otras modificaciones post-traduccionales
                           Lacking H chain C-terminal lysine (CHS K2>del)


 eflapegrastimum #
 eflapegrastim             human granulocyte colony-stimulating factor and human
                           IgG4 Fc dimer linked together with polyethylene glycol
                           derivative, produced in Escherichia coli:
                             α.1 1.9'
                           N ,N -[ω-(oxypropane-1,3-diyl)-α-(propane-
                           1,3-diyl)poly(oxyethylene)] des-(1-L-alanine,37-39)-
                           [18-L-serine(C>S),69-L-serine(P>S)]human granulocyte
                           colony-stimulating factor (G-CSF, pluripoietin) (1-174)-
                           peptide and des-(1-8)-human immunoglobulin G4 Fc
                           fragment (IGHG4*01 H-CH2-CH3) (9'-229')-peptide dimer
                           (11'-11'')-disulfide



78
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73




 éflapégrastim                         le facteur de stimulation de colonies de granulocytes
                                       humain et le dimère du fragment Fc de l’IgG4 humaine,
                                       produits par Escherichia coli, reliés par un radical
                                       substituant dérivé du polyéthylèneglycol:
                                         α.1  1.9'
                                       N ,N -[ω-(oxypropane-1,3-diyl)-α-(propane-
                                       1,3-diyl)poly(oxyethylene)] dès-(1-L-alanine,37-39)-
                                       [18-L-sérine(C>S), 69-L-sérine(P>S)]facteur de stimulation
                                       de colonies de granulocytes humain (G-CSF, pluripoiétine)
                                       (1-174)-peptide et (11'-11'')-disulfure du dimère de
                                       dès-(1-8)-fragment Fc de l’immunoglobuline G4 humaine
                                       (IGHG4*01 H-CH2-CH3) (9'-229')-peptide

 eflapegrastim                         producto de la unión, mediante un radical derivado del
                                       polietilenglicol, del factor estimulante de colonias de
                                       granulocitos humano y el dímero del fragmento Fc de la
                                       IgG4 humana, producidos por Escherichia coli.
                                         α.1  1.9'
                                       N ,N -[ω-(oxipropano-1,3-diil)-α-(propano-
                                       1,3-diil)poli(oxietileno)] des-(1-L-alanina,37-39)-
                                       [18-L-serina(C>S),69-L-serina(P>S)]]factor estimulante de
                                       colonias de granulocitos humano (G-CSF, pluripoyetina)
                                       (1-174)-péptido y (11'-11'')-disulfuro del dímero de
                                       des-(1-8)-fragmento Fc de la inmunoglobulina G4 humana
                                       (IGHG4*01 H-CH2-CH3) (9'-229')-péptido
                                       Human G-CSF derivative sequence / Séquence dérivée du G-CSF humain / Secuencia
                                       derivada de G-CSF humano
                                       TPLGPASSLP QSFLLKSLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
                                       GHSLGIPWAP LSSCSSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
                                       PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
                                       VLVASHLQSF LEVSYRVLRH LAQP                                                 174

                                       hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4
                                                PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50'
                                       EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100'
                                       YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
                                       VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200'
                                       EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                                      229'

                                       hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4
                                                PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50''
                                       EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100''
                                       YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
                                       VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200''
                                       EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                                      229''

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       11'-11'' 36-42 43'-103' 43''-103'' 64-74 149'-207' 149''-207''

                                       Modified residues / Résidus modifiés / Restos modificados        HO
                                                                                                               CH3
                                                                                                        H
                                                    P-T
                                                    9' - 1          N            O                             H
                                                                                           O            N
                                                                                               n        H     CO2H
                                                               H CO2H


 efmoroctocogum alfa #
 efmoroctocog alfa                     recombinant DNA derived (1-742)-(1637-2332)-human
                                       blood coagulation factor VIII fusion protein with
                                       immunoglobulin G1 Fc domain fragment, produced in
                                       HEK293H cells, glycoform alfa:
                                       des-(743-1636)-human blood coagulation factor VIII
                                       (antihemophilic factor, procoagulant component) fusion
                                       protein with human immunoglobulin G1 Fc fragment
                                       (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-6':1447-
                                       9')-bisdisulfide with human immunoglobulin G1 Fc
                                       fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide




                                                                                                                                  79
Recommended INN: List 73                  WHO Drug Information, Vol. 29, No. 1, 2015


 efmoroctocog alfa         (1-742)-(1637-2332)-facteur VIII de coagulation humain
                           protéine de fusion avec le fragment Fc de
                           l’immunoglobuline G1, produite dans les cellules HEK293H
                           à partir d’ADN recombinant, forme glycosylée alfa:
                           dès-(743-1636)-facteur VIII de coagulation humain (facteur
                           antihémophilique, composé procoagulant) protéine de
                           fusion avec le fragment Fc de l’immunoglobuline G1
                           humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-
                           6':1447-9')-bisdisulfure avec le fragment Fc de
                           l’immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-
                           (6-231)-peptide

 efmoroctocog alfa         (1-742)-(1637-2332)-factor VIII de coagulación humano
                           proteína de fusión con el fragmento Fc de la
                           inmunoglobulina G1, producida en las células HEK293H a
                           partir de ADN recombinante, forma glicosilada alfa:
                           des-(743-1636)-factor VIII de coagulación humano (factor
                           antihemofílico, componente procoagulante) proteína de
                           fusión con el fragmento Fc de la inmunoglobulina G1
                           humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido (1444-
                           6':1447-9')-bisdisulfuro con el fragmento Fc de la
                           inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-
                           231)-péptido
                            Fusion protein / Protéine de fusion / Proteína de fusión
                            ATRRYYLGAV      ELSWDYMQSD       LGELPVDARF         PPRVPKSFPF      NTSVVYKKTL      50
                            FVEFTDHLFN      IAKPRPPWMG       LLGPTIQAEV         YDTVVITLKN      MASHPVSLHA      100
                            VGVSYWKASE      GAEYDDQTSQ       REKEDDKVFP         GGSHTYVWQV      LKENGPMASD      150
                            PLCLTYSYLS      HVDLVKDLNS       GLIGALLVCR         EGSLAKEKTQ      TLHKFILLFA      200
                            VFDEGKSWHS      ETKNSLMQDR       DAASARAWPK         MHTVNGYVNR      SLPGLIGCHR      250
                            KSVYWHVIGM      GTTPEVHSIF       LEGHTFLVRN         HRQASLEISP      ITFLTAQTLL      300
                            MDLGQFLLFC      HISSHQHDGM       EAYVKVDSCP         EEPQLRMKNN      EEAEDYDDDL      350
                            TDSEMDVVRF      DDDNSPSFIQ       IRSVAKKHPK         TWVHYIAAEE      EDWDYAPLVL      400
                            APDDRSYKSQ      YLNNGPQRIG       RKYKKVRFMA         YTDETFKTRE      AIQHESGILG      450
                            PLLYGEVGDT      LLIIFKNQAS       RPYNIYPHGI         TDVRPLYSRR      LPKGVKHLKD      500
                            FPILPGEIFK      YKWTVTVEDG       PTKSDPRCLT         RYYSSFVNME      RDLASGLIGP      550
                            LLICYKESVD      QRGNQIMSDK       RNVILFSVFD         ENRSWYLTEN      IQRFLPNPAG      600
                            VQLEDPEFQA      SNIMHSINGY       VFDSLQLSVC         LHEVAYWYIL      SIGAQTDFLS      650
                            VFFSGYTFKH      KMVYEDTLTL       FPFSGETVFM         SMENPGLWIL      GCHNSDFRNR      700
                            GMTALLKVSS      CDKNTGDYYE       DSYEDISAYL         LSKNNAIEPR      SFSQNPPVLK      750
                            RHQREITRTT      LQSDQEEIDY       DDTISVEMKK         EDFDIYDEDE      NQSPRSFQKK      800
                            TRHYFIAAVE      RLWDYGMSSS       PHVLRNRAQS         GSVPQFKKVV      FQEFTDGSFT      850
                            QPLYRGELNE      HLGLLGPYIR       AEVEDNIMVT         FRNQASRPYS      FYSSLISYEE      900
                            DQRQGAEPRK      NFVKPNETKT       YFWKVQHHMA         PTKDEFDCKA      WAYFSDVDLE      950
                            KDVHSGLIGP      LLVCHTNTLN       PAHGRQVTVQ         EFALFFTIFD      ETKSWYFTEN      1000
                            MERNCRAPCN      IQMEDPTFKE       NYRFHAINGY         IMDTLPGLVM      AQDQRIRWYL      1050
                            LSMGSNENIH      SIHFSGHVFT       VRKKEEYKMA         LYNLYPGVFE      TVEMLPSKAG      1100
                            IWRVECLIGE      HLHAGMSTLF       LVYSNKCQTP         LGMASGHIRD      FQITASGQYG      1150
                            QWAPKLARLH      YSGSINAWST       KEPFSWIKVD         LLAPMIIHGI      KTQGARQKFS      1200
                            SLYISQFIIM      YSLDGKKWQT       YRGNSTGTLM         VFFGNVDSSG      IKHNIFNPPI      1250
                            IARYIRLHPT      HYSIRSTLRM       ELMGCDLNSC         SMPLGMESKA      ISDAQITASS      1300
                            YFTNMFATWS      PSKARLHLQG       RSNAWRPQVN         NPKEWLQVDF      QKTMKVTGVT      1350
                            TQGVKSLLTS      MYVKEFLISS       SQDGHQWTLF         FQNGKVKVFQ      GNQDSFTPVV      1400
                            NSLDPPLLTR      YLRIHPQSWV       HQIALRMEVL         GCEAQDLYDK      THTCPPCPAP      1450
                            ELLGGPSVFL      FPPKPKDTLM       ISRTPEVTCV         VVDVSHEDPE      VKFNWYVDGV      1500
                            EVHNAKTKPR      EEQYNSTYRV       VSVLTVLHQD         WLNGKEYKCK      VSNKALPAPI      1550
                            EKTISKAKGQ      PREPQVYTLP       PSRDELTKNQ         VSLTCLVKGF      YPSDIAVEWE      1600
                            SNGQPENNYK      TTPPVLDSDG       SFFLYSKLTV         DKSRWQQGNV      FSCSVMHEAL      1650
                            HNHYTQKSLS      LSPG                                                                1664

                            Immunoglobulin Fc fragment / fragment Fc d'immunoglobuline / fragmento Fc de
                            inmunoglobulina
                            DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50'
                            PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100'
                            CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 150'
                            GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200'
                            NVFSCSVMHE ALHNHYTQKS LSLSPG                                                 226'

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            6'-1444 9'-1447 41'-101'              147'-205' 153-179           248-329       528-554
                            630-711 938-964 1005-1009 1127-1275 1280-1432 1479-1539 1585-1643

                            Modified residues / Résidus modifiés / Restos modificados


                                         Y                        HO        O
                            346, 718, 719, 723, 770, 786                S                   H    NH2
                                     O-sulfoTyr                       O O
                                                                                                  CO2H
                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-41 Asn-77' Asn-239 Asn-916 Asn-1224 Asn-1515




80
WHO Drug Information, Vol. 29, No. 1, 2015                                            Recommended INN: List 73


 efpeglenatidum #
 efpeglenatide                         exenatide derivative and human IgG4 Fc dimer linked
                                       together with polyethylene glycol derivative:
                                         6.27 1.9'
                                       N ,N -[ω-(oxypropane-1,3-diyl)-α-(propane-
                                       1,3-diyl)poly(oxyethylene)] [1-(imidazol-4-ylacetic
                                       acid)]exendin-4 Heloderma suspectum (Gila monster),
                                       human immunoglobulin G4 Fc fragment-(9'-229')-peptide
                                       dimer (11'-11'')-disulfide

 efpèglénatide                         dérivé de l’exénatide et du dimère de l’IgG4 Fc liés par un
                                       pont dérivé du polyéthylèneglycol :
                                         6.27 1.9'
                                       N ,N -[ω-(oxypropane-1,3-diyl)-α-(propane-
                                       1,3-diyl)poly(oxyéthylène)] [1-acide (imidazol-
                                       4-yl)acétique]exendine-4 Heloderma suspectum (monstre
                                       de Gila), fragment Fc de l’immunoglobuline G4 humaine-
                                       (9'-229')-peptide (11'-11'')-disulfure du dimère

 efpeglenatida                         derivado de la exenatida y del dímero de la IgG4 Fc unidos
                                       por un puente derivado del polietilenglicol :
                                         6.27  1.9'
                                       N ,N -[ω-(oxipropano-1,3-diil)-α-(propano-
                                       1,3-diil)poli(oxitileno)] [1-ácido (imidazol-
                                       4-il)acético]exendina-4 Heloderma suspectum (monstruo
                                       de Gila), fragmento Fc de la inmunoglobulina G4 humana-
                                       (9'-229')-péptido (11'-11'')-disulfuro del dímero
                                       Modified exendin-4 / Exendine-4 modifiée / Exendina-4 modificada
                                       HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS                                             39

                                       hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4
                                                PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50'
                                       EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100'
                                       YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
                                       VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200'
                                       EGNVFSCSVM HEALHNHYTQ KSLSLSLGK           229'

                                       hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4
                                                PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50''
                                       EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100''
                                       YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
                                       VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200''
                                       EGNVFSCSVM HEALHNHYTQ KSLSLSLGK           229''

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       11'-11'' 43'-103' 43''-103'' 149'-207' 149''-207''

                                       Modified residues / Résidus modifiés / Restos modificados
                                                                                                             P-K
                                                 H                            S                              9' - 27 HN
                                                 1                            39
                                        (imidazol-4-yl)acetic                                N           O
                                                                         serinamide
                                                acid                                                 CO2H
                                           N                           H         OH
                                                     CO2H                                        H               O        H
                                                                                 NH2                                 n
                                                                   H2N
                                        HN                                                                           H2N       CO2H
                                                                             O


 emactuzumabum #
 emactuzumab                           immunoglobulin G1-kappa, anti-[Homo sapiens CSF1R
                                       (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R,
                                       macrophage colony-stimulating factor 1 receptor, c-fms,
                                       FMS, CD115)], humanized monoclonal antibody;
                                       gamma1 heavy chain (1-446) [humanized VH (Homo
                                       sapiens IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01)
                                       [8.7.10] (1-116) -Homo sapiens IGHG1*01 (CH1 (117-
                                       214), hinge (215-229), CH2 (230-339), CH3 (340-444),
                                       CHS (445-446)) (117-446)], (219-213')-disulfide with kappa
                                       light chain (1’-213’) [humanized V-KAPPA (Homo sapiens
                                       IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -Homo
                                       sapiens IGKC*01 (107'-213')]; dimer (225-225":228-228")-
                                       bisdisulfide




                                                                                                                                   81
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015


 émactuzumab               immunoglobuline G1-kappa, anti-[Homo sapiens CSF1R
                           (récepteur du facteur 1 stimulant de colonies, CSF-1R,
                           CSF-1-R, récepteur du facteur 1 stimulant des colonies de
                           macrophages, c-fms, FMS, CD115)], anticorps monoclonal
                           humanisé;
                           chaîne lourde gamma1 (1-446) [VH humanisé (Homo
                           sapiensIGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-
                           116) -Homo sapiens IGHG1*01 (CH1 (117-214), charnière
                           (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446))
                           (117-446)],(219-213')-disulfure avec la chaîne légère kappa
                           (1’-213’) [V-KAPPA humanisé (Homo sapiens IGKV1-39*01
                           (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -Homo sapiens IGKC*01
                           (107'-213')]; dimère (225-225":228-228")-bisdisulfure
 emactuzumab               inmunoglobulina G1-kappa, anti-[Homo sapiens CSF1R
                           (receptor del factor 1 estimulante de colonias, CSF-1R,
                           CSF-1-R, receptor del factor 1 estimulante de colonias de
                           macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma1 (1-446) [VH humanizado (Homo
                           sapiens IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-
                           116) -Homo sapiens IGHG1*01 (CH1 (117-214), bisagra (215-
                           229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-
                           446)], (219-213')-disulfuro con la cadena ligera kappa (1’-213’)
                           [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (86.30%)
                           -IGKJ2*01) [6.3.8] (1'-106') -Homo sapiens IGKC*01 (107'-
                           213')]; dímero (225-225":228-228")-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SYDISWVRQA       PGQGLEWMGV        50
                           IWTDGGTNYA QKLQGRVTMT TDTSTSTAYM                  ELRSLRSDDT       AVYYCARDQR       100
                           LYFDVWGQGT TVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                           VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                           VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                           PPSRDELTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                           GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASEDVN                  TYVSWYQQKP       GKAPKLLIYA 50
                           ASNRYTGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       SFSYPTFGQG 100
                           TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                           SSPVTKSFNR GEC                                                                213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-95 143-199               260-320   366-424
                                                22''-95'' 143''-199'' 260''-320'' 366''-424''
                           Intra-L (C23-C104) 23'-88' 133'-193'
                                                23'''-88''' 133'''-193'''
                           Inter-H-L (h 5-CL 126) 219-213' 219''-213'''
                           Inter-H-H (h 11, h 14) 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           296, 296''


 emibetuzumabum #
 emibetuzumab              immunoglobulin G4-kappa, anti-[Homo sapiens MET (met
                           proto-oncogene, hepatocyte growth factor receptor, HGFR,
                           scatter factor receptor, HGF/SF receptor, receptor tyrosine-
                           protein kinase c-Met, papillary renal cell carcinoma 2,
                           RCCP2)], humanized monoclonal antibody;
                           gamma4 heavy chain (1-441) [humanized VH (Homo sapiens
                           IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-
                           115)), IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-
                           225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-
                           440), CHS K2>del (441)) (116-441)],(129-215')-disulfide with
                           kappa light chain (1’-215’) [humanized V-KAPPA (Homo
                           sapiens IGKV1-39*01 (84.40%) -IGKJ4*01) [7.3.9] (1'-108') -
                           Homo sapiens IGKC*01 (109'-215')]; dimer (221-221":224-
                           224")-bisdisulfide




82
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73




 émibétuzumab                          immunoglobuline G4-kappa, anti-[Homo sapiens MET
                                       (proto-oncogène met, récepteur du facteur de croissance
                                       hépatocytaire, HGFR, récepteur du facteur de dispersion,
                                       récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase
                                       c-Met, carcinome papillaire à cellules rénales 2, RCCP2)],
                                       anticorps monoclonal humanisé;
                                       chaîne lourde gamma4 (1-441) [VH humanisé (Homo
                                       sapiens IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T
                                       (110) (1-115)), IGHG4*01 (CH1 (116-213), charnière
                                       S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230)
                                       (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)],
                                       (129-215')-disulfure avec la chaîne légère kappa (1’-215’)
                                       [V-KAPPA humanisé (Homo sapiens IGKV1-39*01
                                       (84.40%) -IGKJ4*01) [7.3.9] (1'-108') -Homo sapiens
                                       IGKC*01 (109'-215')]; dimère (221-221":224-224")-
                                       bisdisulfure

 emibetuzumab                          inmunoglobulina G4-kappa, anti-[Homo sapiens MET
                                       (proto-oncogén met, receptor del factor de crecimiento de
                                       hepatocitos, HGFR, receptor del factor de dispersión,
                                       receptor del HGF/SF, receptor proteína-tirosina kinasa c-
                                       Met, carcinoma papilar de células renales 2, RCCP2)],
                                       anticuerpo monoclonal humanizado;
                                       cadena pesada gamma4 (1-441) [VH humanizada (Homo
                                       sapiens IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T
                                       (110) (1-115)) , IGHG4*01 (CH1 (116-213), bisagra S10>P
                                       (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-
                                       335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-
                                       215')-disulfuro con la cadena ligera kappa (1’-215’) [V-
                                       KAPPA humanizado (Homo sapiens IGKV1-39*01
                                       (84.40%) -IGKJ4*01) [7.3.9] (1'-108')-Homo sapiens
                                       IGKC*01 (109'-215')]; dímero (221-221":224-224")-
                                       bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  DYYMHWVRQA       PGQGLEWMGR        50
                                       VNPNRRGTTY NQKFEGRVTM TTDTSTSTAY                  MELRSLRSDD       TAVYYCARAN       100
                                       WLDYWGQGTT VTVSSASTKG PSVFPLAPCS                  RSTSESTAAL       GCLVKDYFPE       150
                                       PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSS       LGTKTYTCNV       200
                                       DHKPSNTKVD KRVESKYGPP CPPCPAPEAA                  GGPSVFLFPP       KPKDTLMISR       250
                                       TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH                  NAKTKPREEQ       FNSTYRVVSV       300
                                       LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT                  ISKAKGQPRE       PQVYTLPPSQ       350
                                       EEMTKNQVSL TCLVKGFYPS DIAVEWESNG                  QPENNYKTTP       PVLDSDGSFF       400
                                       LYSRLTVDKS RWQEGNVFSC SVMHEALHNH                  YTQKSLSLSL       G                441


                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCSVSSSVS                  SIYLHWYQQK       PGKAPKLLIY 50
                                       STSNLASGVP SRFSGSGSGT DFTLTISSLQ                  PEDFATYYCQ       VYSGYPLTFG 100
                                       GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                       VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                       GLSSPVTKSF NRGEC                                                              215

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          142-198       256-316   362-420
                                                             22''-96'' 142''-198'' 256''-316'' 362''-420''
                                       Intra-L (C23-C104) 23'-89'        135'-195'
                                                             23'''-89''' 135'''-195'''
                                       Inter-H-L (CH1 10-CL 126) 129-215' 129''-215'''
                                       Inter-H-H (h 8, h 11)           221-221'' 224-224''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       292, 292''

                                       Other post-translational modifications
                                       Autres modifications post-traductionnelles
                                       Otras modificaciones post-traduccionales
                                       Lacking H chain C-terminal lysine (CHS K2>del)




                                                                                                                                  83
Recommended INN: List 73            WHO Drug Information, Vol. 29, No. 1, 2015




 enadenotucirevum #
 enadenotucirev            chimeric oncolytic adenovirus Ad3/Ad11p containing two
                           deletions in the viral genome in the E3 region (2444 bp)
                           and in the E4 region (24 bp) and 197 non-homologous
                           nucleotides in the E2B region

 énadénotucirev            adénovirus chimérique oncolytique Ad3/Ad11p contenant
                           deux suppressions dans le génome viral, dans la région E3
                           (2444 pb) et dans la région E4 (24 pb) et 197 nucléotides
                           non-homologues dans la région E2B

 enadenotucirev            adenovirus quimérico oncolítico Ad3/Ad11p que contiene
                           dos delecciones en el genoma viral, en la región E3 (2444
                           pb) y en la región E4 (24 pb) y 197 nucléotidos
                           no-homólogos en la región E2B



 enceniclinum
 encenicline               N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-
                           1-benzothiophene-2-carboxamide

 encénicline               N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-
                           1-benzothiophène-2-carboxamide

 enceniclina               N-[(3R)-1-azabiciclo[2.2.2]octan-3-il]-7-cloro-
                           1-benzotiofeno-2-carboxamida

                           C16H17ClN2OS

                              N
                                        O

                                    N
                                  H H
                                            S


                                                Cl




 esuberaprostum
 esuberaprost              (+)-4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4S)-3-
                           hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-
                           1H-cyclopenta[b][1]benzofuran-5-yl}butanoic acid

 ésubéraprost              (+)-acide4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4S)-3-
                           hydroxy-4-méthyloct-1-én-6-yn-1-yl]-2,3,3a,8b-tétrahydro-
                           1H-cyclopenta[b][1]benzofuran-5-yl}butanoïque

 esuberaprost              (+)-ácido 4-{(1R,2R,3aS,8bS)-2-hidroxi-1-[(1E,3S,4S)-3-
                           hidroxi-4-metiloct-1-en-6-in-1-il]-2,3,3a,8b-tetrahidro-
                           1H-ciclopenta[b][1]benzofuran-5-il}butanoico




84
WHO Drug Information, Vol. 29, No. 1, 2015                                            Recommended INN: List 73


                                       C24H30O5

                                                                                           CO2H
                                                        H
                                                                O
                                        HO
                                            H
                                                H           H


                                                HO
                                                     H
                                                     H3C            H                CH3


 evofosfamidum
 evofosfamide                          (1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N'-bis(2-
                                       bromoethyl)phosphorodiamidate

 évofosfamide                          N,N'-bis(2-bromoéthyl)phosphorodiamidate de (1-méthyl-
                                       2-nitro-1H-imidazol-5-yl)méthyle

 evofosfamida                          N,N'-bis(2-bromoetil)fosforodiamidato de (1-metil-2-nitro-
                                       1H-imidazol-5-il)metilo

                                       C9H16Br2N5O4P
                                                                                      Br
                                                                        HN
                                                                O
                                                                        P
                                                                O
                                            N                           HN
                                                    N                                 Br
                                                        CH3
                                        O2N



 ferricum maltolum
 ferric maltol                         tris(2-methyl-4-oxo-κO-4H-pyran-3-olato-κO)iron(III)

 maltol ferrique                       tris(2-méthyl-4-oxo-κO-4H-pyran-3-olato-κO)fer(III)

 maltol férrico                        tris(2-metil-4-oxo-κO-4H-piran-3-olato-κO)hierro(III)

                                       C18H15FeO9
                                                                                 O

                                             CH3                O                    CH3
                                                        O                    O
                                        O
                                                                Fe
                                                        O                    O
                                                                O


                                                            H3C              O



 filociclovirum
 filociclovir                          2-amino-9-{(Z)-[2,2-
                                       bis(hydroxymethyl)cyclopropylidene]methyl}-1,9-dihydro-
                                       6H-purin-6-one




                                                                                                           85
Recommended INN: List 73               WHO Drug Information, Vol. 29, No. 1, 2015




 filociclovir              2-amino-9-{(Z)-[2,2-
                           bis(hydroxyméthyl)cyclopropylidène]méthyl}-1,9-dihydro-
                           6H-purin-6-one

 filociclovir              2-amino-9-{(Z)-[2,2-bis(hidroximetil)ciclopropilideno]metil}-
                           1,9-dihidro-6H-purin-6-ona

                           C11H13N5O3

                                       O

                                            N
                                  HN                  OH

                            H2N        N    N
                                                         OH




 firivumabum #
 firivumab                 immunoglobulin G1-kappa, anti-[influenza A virus
                           hemagglutinin HA], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV1-
                           69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -
                           IGHG1*03 (CH1 (124-221), hinge (222-236), CH2 (237-
                           346), CH3 E12>D (362), M14>L (364), A110>G (437)
                           (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide
                           with kappa light chain (1'-214') [Homo sapiens V-KAPPA
                           (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -
                           IGKC*01 (108'-214')]; dimer (232-232'':235-235'')-
                           bisdisulfide

 firivumab                 immunoglobuline G1-kappa, anti-[hémagglutinine HA du
                           virus de la grippe A], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-453) [Homo sapiens VH
                           (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-
                           123) -IGHG1*03 (CH1 (124-221), charnière (222-236),
                           CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G
                           (437) (347-451), CHS (452-453)) (124-453)], (226-214')-
                           disulfure avec la chaîne légère kappa (1'-214') [Homo
                           sapiens V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-
                           232'':235-235'')-bisdisulfure

 firivumab                 inmunoglobulina G1-kappa, anti-[hemaglutinina HA del
                           virus de la gripe A], anticuerpo monoclonal de Homo
                           sapiens;
                           cadena pesada gamma1 (1-453) [Homo sapiens VH
                           (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-
                           123) -IGHG1*03 (CH1 (124-221), bisagra (222-236), CH2
                           (237-346), CH3 E12>D (362), M14>L (364), A110>G (437)
                           (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro
                           con la cadena ligera kappa (1'-214') [Homo sapiens
                           V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-
                           107') -IGKC*01 (108'-214')]; dímero (232-232'':235-235'')-
                           bisdisulfuro




86
WHO Drug Information, Vol. 29, No. 1, 2015                                       Recommended INN: List 73




                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKMPGSSVKV SCKTSGVFFS                   SHAISWVRQA      PGQGLEWMGG        50
                                       ISPMFGTTHY AQKFQGRVTI TADQSTTTAY                   MELTSLTSED      TAVYYCARDG       100
                                       AGSYYPLNWF DPWGQGTLVT VSSASTKGPS                   VFPLAPSSKS      TSGGTAALGC       150
                                       LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                   QSSGLYSLSS      VVTVPSSSLG       200
                                       TQTYICNVNH KPSNTKVDKR VEPKSCDKTH                   TCPPCPAPEL      LGGPSVFLFP       250
                                       PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                   FNWYVDGVEV      HNAKTKPREE       300
                                       QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                   NKALPAPIEK      TISKAKGQPR       350
                                       EPQVYTLPPS RDELTKNQVS LTCLVKGFYP                   SDIAVEWESN      GQPENNYKTT       400
                                       PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                   CSVMHEGLHN      HYTQKSLSLS       450
                                       PGK                                                                                 453

                                       Light chain / Chaîne légère / Cadena ligera
                                       EIVLTQSPAT LSLSPGERAT LSCRASENIW                   NNLAWYQQKP      GQAPRLLISG 50
                                       ASTGATGVPS RFRGSGSRTE FTLTISSLQS                   EDFAIYFCQQ      YNSWPRTFGP 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                   SVVCLLNNFY      PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                   LSKADYEKHK      VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          150-206       267-327   373-431
                                                             22''-96'' 150''-206'' 267''-327'' 373''-431''
                                       Intra-L (C23-C104) 23'-88'         134'-194'
                                                             23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 226-214' 226''-214'''
                                       Inter-H-H (h 11, h 14) 232-232'' 235-235''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       303, 303''



 fosdagrocoratum
 fosdagrocorat                         (2R,4aS,10aR)-4a-benzyl-7-[(2-methylpyridin-
                                       3-yl)carbamoyl]-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-
                                       octahydrophenanthren-2-yl dihydrogen phosphate

 fosdagrocorat                         dihydrogénophosphate de (2R,4aS,10aR)-4a-benzyl-
                                       7-[(2-méthylpyridin-3-yl)carbamoyl]-2-(trifluorométhyl)-
                                       1,2,3,4,4a,9,10,10a-octahydrophénanthrén-2-yle

 fosdagrocorat                         dihidrógenofosfato de (2R,4aS,10aR)-4a-bencil-
                                       7-[(2-metilpiridin-3-il)carbamoil]-2-(trifluorometil)-
                                       1,2,3,4,4a,9,10,10a-octahidrofenantren-2-ilo

                                       C29H30F3N2O5P
                                                                                                O
                                                                                                    OH
                                                                                          O     P
                                                                                              CF3 OH

                                             CH3
                                                     H                                H
                                                     N
                                        N
                                                          O



 funapidum
 funapide                              (3'S)-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}-2H,6H-
                                       spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one

 funapide                              (3'S)-1'-{[5-(trifluorométhyl)furan-2-yl]méthyl}-2H,6H-
                                       spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one

 funapida                              (3'S)-1'-{[5-(trifluorometil)furan-2-il]metil}-2H,6H-
                                       espiro[furo[2,3-f][1,3]benzodioxol-7,3'-indol]-2'(1'H)-ona




                                                                                                                                 87
Recommended INN: List 73               WHO Drug Information, Vol. 29, No. 1, 2015


                           C22H14F3NO5

                              O                     O

                              O
                                        O
                                                    N
                            F3 C       O




 furaprevirum
 furaprevir                cyclopentyl {(2R,6S,12Z,13aS,14aR,16aS)-14a-[(1-
                           methylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-
                           [(propan-2-yl)oxy]phenyl}benzofuro[3,2-d]pyrimidin-
                           4-yl)oxy]-5,16-dioxo-
                           1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                           hexadecahydrocyclopropa[e]pyrrolo[1,2-
                           a][1,4]diazacyclopentadecin-6-yl}carbamate

 furaprévir                {(2R,6S,12Z,13aS,14aR,16aS)-14a-[(1-
                           méthylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-
                           [(propan-2-yl)oxy]phényl}benzofuro[3,2-d]pyrimidin-
                           4-yl)oxy]-5,16-dioxo-
                           1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                           hexadécahydrocyclopropa[e]pyrrolo[1,2-
                           a][1,4]diazacyclopentadécin-6-yl}carbamate de
                           cyclopentyle

 furaprevir                {(2R,6S,12Z,13aS,14aR,16aS)-14a-[(1-metilciclopropano-
                           1-sulfonamido)carbonil]-2-[(2-{4-[(propan-2-
                           il)oxi]fenil}benzofuro[3,2-d]pirimidin-4-il)oxi]-5,16-dioxo-
                           1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
                           hexadecahidrociclopropa[e]pirrolo[1,2-
                           a][1,4]diazaciclopentadecin-6-il}carbamato de ciclopentilo

                           C47H56N6O10S

                                        O
                                       O S          CH3
                                   O       NH
                                                O
                                                        H       O
                                                                        N
                                           N                    H
                                           H
                                   H       O            N       O   N           CH3

                                                        H O                 O     CH3
                                                HN
                                                            O


 gedatolisibum
 gedatolisib               N-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-
                           N'-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}urea

 gédatolisib               N-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-
                           N'-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phényl}urée




88
WHO Drug Information, Vol. 29, No. 1, 2015                              Recommended INN: List 73




 gedatolisib                           N-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-
                                       N'-{4-[4,6-di(morfolin-4-il)-1,3,5-triazin-2-il]fenil}urea

                                       C32H41N9O4

                                                      O


                                                      N

                                                  N       N                              O

                                              N       N                     O                N
                                        O                                                               CH3
                                                                        N       N                   N
                                                                        H       H
                                                                                                    CH3



 glasdegibum
 glasdegib                             N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-
                                       4-yl]-N'-(4-cyanophenyl)urea

 glasdégib                             N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-méthylpipéridin-
                                       4-yl]-N'-(4-cyanophényl)urée

 glasdegib                             N-[(2R,4R)-2-(1H-benzoimidazol-2-il)-1-metilpiperidin-4-il]-
                                       N'-(4-cianofenil)urea

                                       C21H22N6O

                                        NC                                      CH3
                                                              O             N
                                                                                     N
                                                          N       N
                                                          H       H H       H
                                                                                HN




 idasanutlinum
 idasanutlin                           4-[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-
                                       2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-
                                       2-carboxamido]-3-methoxybenzoic acid

 idasanutline                          acide 4-[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophényl)-
                                       4-(4-chloro-2-fluorophényl)-4-cyano-5-(2,2-
                                       diméthylpropyl)pyrrolidine-2-carboxamido]-
                                       3-méthoxybenzoïque

 idasanutlina                          ácido 4-[(2R,3S,4R,5S)-3-(3-cloro-2-fluorofenil)-4-(4-cloro-
                                       2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)pirrolidina-
                                       2-carboxamido]-3-metoxibenzoico




                                                                                                        89
Recommended INN: List 73            WHO Drug Information, Vol. 29, No. 1, 2015


                           C31H29Cl2F2N3O4

                                                            CO2H


                                   CH3        HN
                            H 3C         H
                                    H    N           OCH3
                            H 3C
                                                O
                                   NC         H F
                                         H
                                                      Cl
                                          F

                              Cl



 imalumabum #
 imalumab                  immunoglobulin G1-kappa, anti-[Homo sapiens MIF
                           (macrophage migration inhibitory factor, glycosylation-
                           inhibiting factor, GLIF, GIF)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-
                           23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -
                           IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 (232-
                           341), CH3 (342-446), CHS (447-448)) (119-448)], (221-
                           214')-disulfide with kappa light chain (1'-214') [Homo
                           sapiens V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (227-
                           227'':230-230'')-bisdisulfide

 imalumab                  immunoglobuline G1-kappa, anti-[Homo sapiens MIF
                           (facteur inhibiteur de la migration des macrophages,
                           facteur inhibant la glycosylation, GLIF, GIF)], Homo
                           sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-448) [Homo sapiens VH
                           (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-
                           118) -IGHG1*03 (CH1 (119-216), charnière (217-231),
                           CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-
                           448)], (221-214')-disulfure avec la chaîne légère kappa (1'-
                           214') [Homo sapiens V-KAPPA (IGKV1-39*01 (85.30%) -
                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère
                           (227-227'':230-230'')-bisdisulfure

 imalumab                  inmunoglobulina G1-kappa, anti-[Homo sapiens MIF
                           (facteur inhibidor de la migración de macrófagos, factor
                           inhibidor de la glicosilación, GLIF, GIF)], anticuerpo
                           monoclonal de Homo sapiens ;
                           cadena pesada gamma1 (1-448) [Homo sapiens VH
                           (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-
                           118) -IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2
                           (232-341), CH3 (342-446), CHS (447-448)) (119-448)],
                           (221-214')-disulfuro con la cadena kappa (1'-214') [Homo
                           sapiens V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (227-
                           227'':230-230'')-bisdisulfuro




90
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLLESGGG LVQPGGSLRL SCAASGFTFS                    IYSMNWVRQA     PGKGLEWVSS        50
                                       IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY                    LQMNSLRAED     TAVYYCAGSQ       100
                                       WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA                    PSSKSTSGGT     AALGCLVKDY       150
                                       FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                    YSLSSVVTVP     SSSLGTQTYI       200
                                       CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                    PAPELLGGPS     VFLFPPKPKD       250
                                       TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                    DGVEVHNAKT     KPREEQYNST       300
                                       YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                    APIEKTISKA     KGQPREPQVY       350
                                       TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                    EWESNGQPEN     NYKTTPPVLD       400
                                       SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                    EALHNHYTQK     SLSLSPGK         448

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCRSSQRIM                    TYLNWYQQKP     GKAPKLLIFV 50
                                       ASHSQSGVPS RFRGSGSETD FTLTISGLQP                    EDSATYYCQQ     SFWTPLTFGG 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                    SVVCLLNNFY     PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                    LSKADYEKHK     VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96 145-201 262-322 368-426
                                         22''-96'' 145''-201'' 262''-322'' 368''-426''
                                       Intra-L (C23-C104) 23'-88' 134'-194'
                                         23'''-88''' 134'''-194'''
                                       Inter-H-L (h 5-CL 126) 221-214' 221''-214'''
                                       Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       298, 298''




 indoximodum
 indoximod                             1-methyl-D-tryptophan

 indoximod                             1-méthyl-D-tryptophane

 indoximod                             1-metil-D-triptófano

                                       C12H14N2O2

                                          H3C
                                                N
                                                             H     NH2

                                                                     CO2H



 lemborexantum
 lemborexant                           (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-
                                       2-(3-fluorophenyl)-N-(5-fluoropyridin-
                                       2-yl)cyclopropanecarboxamide

 lemborexant                           (1R,2S)-2-{[(2,4-diméthylpyrimidin-5-yl)oxy]méthyl}-
                                       2-(3-fluorophényl)-N-(5-fluoropyridin-
                                       2-yl)cyclopropanecarboxamide

 lemborexant                           (1R,2S)-2-{[(2,4-dimetilpirimidin-5-il)oxi]metil}-
                                       2-(3-fluorofenil)-N-(5-fluoropiridin-
                                       2-il)ciclopropanocarboxamida

                                       C22H20F2N4O2

                                        H3C          N        CH3                                         F
                                                                                  O
                                                N
                                                              O                        N         N
                                                                                       H
                                                                             H


                                                                                  F




                                                                                                                                   91
Recommended INN: List 73                  WHO Drug Information, Vol. 29, No. 1, 2015




 lenzilumabum #
 lenzilumab                immunoglobulin G1-kappa, anti-[Homo sapiens CSF2
                           (colony stimulating factor 2 (granulocyte-macrophage),
                           granulocyte-macrophage colony stimulating factor, GM-
                           CSF)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV1-
                           3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -
                           IGHG1*03 (CH1 (120-217), hinge (218-232), CH2 (233-
                           342), CH3 (343-447), CHS (448-449)) (120-449)], (222-
                           214')-disulfide with kappa light chain (1'-214') [Homo
                           sapiens V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (228-
                           228'':231-231'')-bisdisulfide

 lenzilumab                immunoglobuline G1-kappa, anti-[Homo sapiens CSF2
                           (facteur 2 stimulant de colonies (granulocyte-macrophage),
                           facteur stimulant des colonies de granulocytes et
                           macrophages, GM-CSF)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma1 (1-449) [Homo sapiens VH
                           (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119)
                           -IGHG1*03 (CH1 (120-217), charnière (218-232), CH2
                           (233-342), CH3 (343-447), CHS (448-449)) (120-449)],
                           (222-214')-disulfure avec la chaîne légère kappa (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-20*01 (85.40%) -
                           IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère
                           (228-228'':231-231'')-bisdisulfure

 lenzilumab                inmunoglobulina G1-kappa, anti-[Homo sapiens CSF2
                           (factor 2 estimulante de colonias (granulocitos-
                           macrófagos), factor estimulante de colonias de
                           granulocitos y macrófagos, GM-CSF)], anticuerpo
                           monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-449) [Homo sapiens VH
                           (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119)
                           -IGHG1*03 (CH1 (120-217), bisagra (218-232), CH2 (233-
                           342), CH3 (343-447), CHS (448-449)) (120-449)], (222-
                           214')-disulfuro con la ligera kappa (1'-214') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-
                           107') -IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-
                           bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYSFT                  NYYIHWVRQA       PGQRLEWMGW        50
                           INAGNGNTKY SQKFQGRVTI TRDTSASTAY                  MELSSLRSED       TAVYYCVRRQ       100
                           RFPYYFDYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSVSPGERAT LSCRASQSVG                  TNVAWYQQKP       GQAPRVLIYS 50
                           TSSRATGITD RFSGSGSGTD FTLTISRLEP                  EDFAVYYCQQ       FNKSPLTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          146-202       263-323   369-427
                                                 22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L (C23-C104) 23'-88'        134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 222-214' 222''-214'''
                           Inter-H-H (h 11, h 14) 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           299, 299''




92
WHO Drug Information, Vol. 29, No. 1, 2015                                          Recommended INN: List 73


 lonoctocogum alfa #
 lonoctocog alfa                       recombinant DNA derived B domain deleted single-chain
                                       human blood coagulation factor VIII, produced in Chinese
                                       hamster ovary (CHO) D944 cells, glycoform alfa:
                                       des-(765-1652)-human blood coagulation factor VIII
                                       (antihemophilic factor, procoagulant component)

 lonoctocog alfa                       facteur VIII de coagulation humain dont le domaine B a été
                                       supprimé, chaîne unique, produit par les cellules
                                       ovariennes de hamsters chinois (CHO) D944 à partir
                                       d'ADN recombinant, forme glycosylée alfa;
                                       dès-(765-1652)-facteur VIII de coagulation humain (facteur
                                       antihémophilique, composé procoagulant)

 lonoctocog alfa                       factor VIII de coagulación humano al que se ha suprimido
                                       el dominio B, monocatenario, producido por células
                                       ováricas de hamster chino (CHO) D944 a partir de ADN
                                       recombinante, forma glicosilada alfa;
                                       des-(765-1652)-factor VIII de coagulación humano (factor
                                       antihemofílico, componente procoagulante)
                                       Sequence / Séquence / Secuencia
                                       ATRRYYLGAV ELSWDYMQSD LGELPVDARF                  PPRVPKSFPF       NTSVVYKKTL       50
                                       FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                  YDTVVITLKN       MASHPVSLHA       100
                                       VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                  GGSHTYVWQV       LKENGPMASD       150
                                       PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                  EGSLAKEKTQ       TLHKFILLFA       200
                                       VFDEGKSWHS ETKNSLMQDR DAASARAWPK                  MHTVNGYVNR       SLPGLIGCHR       250
                                       KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                  HRQASLEISP       ITFLTAQTLL       300
                                       MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                  EEPQLRMKNN       EEAEDYDDDL       350
                                       TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                  TWVHYIAAEE       EDWDYAPLVL       400
                                       APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                  YTDETFKTRE       AIQHESGILG       450
                                       PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                  TDVRPLYSRR       LPKGVKHLKD       500
                                       FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                  RYYSSFVNME       RDLASGLIGP       550
                                       LLICYKESVD QRGNQIMSDK RNVILFSVFD                  ENRSWYLTEN       IQRFLPNPAG       600
                                       VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                  LHEVAYWYIL       SIGAQTDFLS       650
                                       VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                  SMENPGLWIL       GCHNSDFRNR       700
                                       GMTALLKVSS CDKNTGDYYE DSYEDISAYL                  LSKNNAIEPR       SFSQNSRHPS       750
                                       TRQKQFNATT IPENTTLQSD QEEIDYDDTI                  SVEMKKEDFD       IYDEDENQSP       800
                                       RSFQKKTRHY FIAAVERLWD YGMSSSPHVL                  RNRAQSGSVP       QFKKVVFQEF       850
                                       TDGSFTQPLY RGELNEHLGL LGPYIRAEVE                  DNIMVTFRNQ       ASRPYSFYSS       900
                                       LISYEEDQRQ GAEPRKNFVK PNETKTYFWK                  VQHHMAPTKD       EFDCKAWAYF       950
                                       SDVDLEKDVH SGLIGPLLVC HTNTLNPAHG                  RQVTVQEFAL       FFTIFDETKS       1000
                                       WYFTENMERN CRAPCNIQME DPTFKENYRF                  HAINGYIMDT       LPGLVMAQDQ       1050
                                       RIRWYLLSMG SNENIHSIHF SGHVFTVRKK                  EEYKMALYNL       YPGVFETVEM       1100
                                       LPSKAGIWRV ECLIGEHLHA GMSTLFLVYS                  NKCQTPLGMA       SGHIRDFQIT       1150
                                       ASGQYGQWAP KLARLHYSGS INAWSTKEPF                  SWIKVDLLAP       MIIHGIKTQG       1200
                                       ARQKFSSLYI SQFIIMYSLD GKKWQTYRGN                  STGTLMVFFG       NVDSSGIKHN       1250
                                       IFNPPIIARY IRLHPTHYSI RSTLRMELMG                  CDLNSCSMPL       GMESKAISDA       1300
                                       QITASSYFTN MFATWSPSKA RLHLQGRSNA                  WRPQVNNPKE       WLQVDFQKTM       1350
                                       KVTGVTTQGV KSLLTSMYVK EFLISSSQDG                  HQWTLFFQNG       KVKVFQGNQD       1400
                                       SFTPVVNSLD PPLLTRYLRI HPQSWVHQIA                  LRMEVLGCEA       QDLY             1444

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       153-179 248-329 528-554 630-711 944-970 1011-1015 1133-1281 1286-1438

                                       Modified residues / Résidus modifiés / Restos modificados
                                                   Y
                                       346-718-719-723-776-792                  HO     O
                                                                                     S                   H   NH2
                                               O-sulfoTyr
                                                                                     O O
                                                                                                              CO2H

                                       Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                       Asn-41 Asn-239           Asn-757 Asn-764 Asn-922 Asn-1230
                                       Glycosylation site (O) / Site de glycosylation (O) / Posición de glicosilación (O)
                                       Ser-743


 lulizumabum pegolum #
 lulizumab pegol                       immunoglobulin V-kappa pegylated, anti-[Homo sapiens
                                       CD28 (TP44, T cell specific surface glycoprotein CD28)],
                                       humanized monoclonal antibody;
                                       V-kappa domain (1-107) [humanized V-KAPPA (Homo
                                       sapiens IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01
                                       G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugated via
                                       a linker of the maleimide group (thioether bond with
                                       cysteinyl 86 (70)) to two linear chains of methoxy
                                       polyethylene glycol 20 (mPEG20)



                                                                                                                                         93
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




 lulizumab pégol           immunoglobuline V-kappa pégylé, anti-[Homo sapiens
                           CD28 (TP44, glycoprotéine de surface CD28 spécifique
                           des cellules T)], anticorps monoclonal humanisé;
                           domaine V-kappa (1-107) [V-KAPPA humanisé (Homo
                           sapiens IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01
                           G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugué via
                           un linker du groupe maléimide (liaison thioéther avec
                           cystéinyl 86 (70)) à deux chaînes linéaires de méthoxy
                           polyéthylène glycol 20 (mPEG20)

 lulizumab pegol           inmunoglobulina V-kappa pegilada, anti-[Homo sapiens
                           CD28 (TP44, glicoproteína de superficie CD28 específico
                           de células T)], anticuerpo monoclonal humanizado;
                           dominio V-kappa (1-107) [V-KAPPA humanizado (Homo
                           sapiens IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01
                           G119>S (99)) [6.3.9] (1-107)] -arginil (108); conjugado
                           mediante conector del grupo maleimida (unión tioéter con
                           cisteinil 86 (70)) con dos cadenas lineales de metoxi
                           polietilen glicol 20 (mPEG20)
                           DIQMTQSPSS LSASVGDRVT ITCRASRPIW PFLEWYQQKP GKAPKLLIYF 50
                           TSRLRHGVPS RFSGSGSGTC FTLTISSLQP EDFATYYCLQ NVANPATFSQ 100
                           GTKVEIKR                                               108

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-L (C23-C104) 23-88

                           Pegylation site / Site de pegylation / Posición de pegilación
                           D86>C:
                           70


 lumretuzumabum #
 lumretuzumab              immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3
                           (receptor tyrosine-protein kinase erbB-3, HER3)],
                           humanized monoclonal antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo
                           sapiens IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01)
                           [8.8.13] (1-120) -Homo sapiens IGHG1*01(CH1 (121-218),
                           hinge (219-233), CH2 (234-343), CH3 (344-448), CHS
                           K2>del (449)) (121-449)],(223-220')-disulfide with kappa
                           light chain (1’-220’) [humanized V-KAPPA (Homo sapiens
                           IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') -Homo
                           sapiens IGKC*01 (114'-220')]; dimer (229-229":232-232")-
                           bisdisulfide

 lumrétuzumab              immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3
                           (récepteur tyrosine-protéine kinase erbB3, HER3)],
                           anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo
                           sapiensIGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13]
                           (1-120) -Homo sapiens IGHG1*01(CH1 (121-218),
                           charnière (219-233), CH2 (234-343), CH3 (344-448), CHS
                           K2>del (449)) (121-449)],(223-220')-disulfure avec la
                           chaîne légère kappa (1’-220’) [V-KAPPA humanisé (Homo
                           sapiens IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113')
                           -Homo sapiens IGKC*01 (114'-220')]; dimère (229-
                           229":232-232")-bisdisulfure




94
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73




 lumretuzumab                          inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3
                                       (receptor tirosina-proteína kinasa erbB3, HER3)],
                                       anticuerpo monoclonal humanizado;
                                       cadena pesada gamma1 (1-449) [VH humanizada (Homo
                                       sapiens IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01)
                                       [8.8.13] (1-120) -Homo sapiens IGHG1*01 (CH1 (121-
                                       218), bisagra (219-233), CH2 (234-343), CH3 (344-448),
                                       CHS K2>del (449)) (121-449)], (223-220')-disulfuro con la
                                       cadena ligera kappa (1’-220’) [V-KAPPA humanizada
                                       (Homo sapiens IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9]
                                       (1'-113') -Homo sapiens IGKC*01 (114'-220')]; dímero
                                       (229-229":232-232")-bisdisulfuro
                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFR                   SSYISWVRQA      PGQGLEWMGW        50
                                       IYAGTGSPSY NQKLQGRVTM TTDTSTSTAY                   MELRSLRSDD      TAVYYCARHR       100
                                       DYYSNSLTYW GQGTLVTVSS ASTKGPSVFP                   LAPSSKSTSG      GTAALGCLVK       150
                                       DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                   GLYSLSSVVT      VPSSSLGTQT       200
                                       YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                   PCPAPELLGG      PSVFLFPPKP       250
                                       KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                   YVDGVEVHNA      KTKPREEQYN       300
                                       STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                   LPAPIEKTIS      KAKGQPREPQ       350
                                       VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                   AVEWESNGQP      ENNYKTTPPV       400
                                       LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                   MHEALHNHYT      QKSLSLSPG        449

                                       Light chain / Chaîne légère / Cadena ligera
                                       DIVMTQSPDS LAVSLGERAT INCKSSQSVL                   NSGNQKNYLT      WYQQKPGQPP 50
                                       KLLIYWASTR ESGVPDRFSG SGSGTDFTLT                   ISSLQAEDVA      VYYCQSDYSY 100
                                       PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ                   LKSGTASVVC      LLNNFYPREA 150
                                       KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                   LSSTLTLSKA      DYEKHKVYAC 200
                                       EVTHQGLSSP VTKSFNRGEC                                                         220

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96          147-203       264-324   370-428
                                                             22''-96'' 147''-203'' 264''-324'' 370''-428''
                                       Intra-L (C23-C104) 23'-94'         140'-200'
                                                             23'''-94''' 140'''-200'''
                                       Inter-H-L (h 5-CL 126) 223-220' 223''-220'''
                                       Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       300, 300''
                                       Enriched in bisected non-fucosylated oligosaccharides
                                       Enrichi en oligosaccharides non-fucosylés bissectés
                                       Enriquecido con oligosacáridos bisecados no fucosilados

                                       Other post-translational modifications
                                       Autres modifications post-traductionnelles
                                       Otras modificaciones post-traduccionales
                                       Lacking H chain C-terminal lysine (CHS K2>del)


 merotocinum
 merotocin                             N-(4-sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-
                                       L-asparaginyl-L-cysteinyl-N-[(4-fluorophenyl)methyl]glycyl-
                                       L-leucylglycinamide cyclic (1-5)-thioether

 mérotocine                            (1-5)-thioéthercyclique du N-(4-sulfanylbutanoyl)-L-tyrosyl-
                                       L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cystéinyl-
                                       N-[(4-fluorophényl)méthyl]glycyl-L-leucylglycinamide

 merotocina                            (1-5)-tioetercíclico del N-(4-sulfanilbutanoil)-L-tirosil-
                                       L-isoleucil-L-glutaminil-L-asparaginil-L-cisteinil-
                                       N-[(4-fluorofenil)metil]glicil-L-leucilglicinamida

                                       C48H68FN11O12S
                                                                     F



                                                          S                     H             O
                                                                                      N             Leu    Gly NH2
                                              Tyr    Ile Gln      Asn N
                                                                      H
                                        O                                         O




                                                                                                                                 95
Recommended INN: List 73             WHO Drug Information, Vol. 29, No. 1, 2015




 mibenratidum
 mibenratide               an 18 amino acid cyclic peptide largely homologous to
                           amino acids 202-220 of the β1-adrenergic receptor second
                           extracellular loop (AR-ECII) that binds to anti-β1-AR
                           pathological autoantibodies:
                           cyclo(L-alanyl-L-arginyl-L-arginyl-L-cysteinyl-L-tyrosyl-
                           L-asparaginyl-L-α-aspartyl-L-prolyl-L-lysyl-L-cysteinyl-
                           L-seryl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-glutaminyl-
                           L-alanyl-L-α-aspartyl-L-α-glutamyl), cyclic (4-10)-disulfide

 mibenratide               peptide cyclique de 18 acides aminés largement
                           homologue aux acides aminés 202-220 de la seconde
                           boucle extracellulaire de l'adrénorécepteur β1 (AR-ECII)
                           qui se lie aux autoanticorps anti-β1-AR pathologiques:
                           (4-10)-disulfure cyclique du cyclo(L-alanyl-L-arginyl-
                           L-arginyl-L-cystéinyl-L-tyrosyl-L-asparaginyl-L-α-aspartyl-
                           L-prolyl-L-lysyl-L-cystéinyl-L-séryl-L-α-aspartyl-
                           L-phénylalanyl-L-valyl-L-glutaminyl-L-alanyl-L-α-aspartyl-
                           L-α-glutamyl)

 mibenratida               péptido cíclico de 18 aminoácidos altamente homólogo a
                           los aminoácidos 202-220 del segundo bucle extracelular
                           del adrenoreceptor β1 (AR-ECII) que se une a los
                           autoanticuerpos anti-β1-AR patológicos:
                           (4-10)-disulfuro cíclico del ciclo (L-alanil-L-arginil-L-arginil-
                           L-cisteinil-L-tirosil-L-asparaginil-L-α-aspartil-L-prolil-L-lisil-
                           L-cisteinil-L-seril-L-α-aspartil-L-fenilalanil-L-valil-L-glutaminil-
                           L-alanil-L-α-aspartil-L-α-glutamil)

                           C87H129N27O30S2

                               Ala   Arg   Arg Cys     Tyr Asn Asp Pro         Lys
                                1
                              Glu Asp Ala        Gln   Val Phe Asp Ser Cys
                               18                                               10



 modimelanotidum
 modimelanotide            acetylhexa-L-lysyl[human melanotropin alpha (alpha-MSH)]

 modimélanotide            acétylhexa-L-lysyl[mélanotropine alpha humaine (alpha-
                           MSH)]

 modimelanotida            acetilhexa-L-lisil[melanotropina alfa humana (alfa-MSH)]

                           C113H181N33O25S

                              O
                                     Lys   Lys   Lys   Lys   Lys   Lys   Ser   Tyr   Ser Met
                                                                                          10
                            H3C

                              Glu    His Phe Arg       Trp   Gly   Lys   Pro   Val NH2
                                                                               19




96
WHO Drug Information, Vol. 29, No. 1, 2015                               Recommended INN: List 73


 mongersenum
 mongersen                             all-P-ambo-2'-deoxy-P-thioguanylyl-(3'→5')-P-
                                       thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-
                                       (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-
                                       thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-
                                       deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                       (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-
                                       2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                       deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-
                                       (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-
                                       P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                                       deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-
                                       (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxycytidine

 mongersen                             tout-P-ambo-2'-déoxy-P-thioguanylyl-(3'→5')-P-
                                       thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-
                                       (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-P-
                                       thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-
                                       déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                       (3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-
                                       2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                       déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-
                                       (3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-5-méthyl-
                                       P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                       déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-
                                       (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxycytidine

 mongersén                             todo-P-ambo-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-
                                       (3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                                       tioguanilil-(3'→5')-2'-desoxi-P-tioctidlil-(3'→5')-2'-desoxi-P-
                                       tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                                       tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-
                                       2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-
                                       P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-
                                       P-tiocitidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-
                                       desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-
                                       desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-
                                       2'-desoxicitidina

                                       C200H261N69O107P20S20

                                       (3'-5')d(P-thio)(G-T-m5C-G-C-C-C-C-T-T-C-T-C-C-C-m5C-G-C-A-G-C)


                                        m5C                  O       N     NH2

                                                         O       N
                                              HO                           CH3


                                                    HO

 napabucasinum
 napabucasin                           2-acetylnaphtho[2,3-b]furan-4,9-dione

 napabucasine                          2-acétylnaphtho[2,3-b]furan-4,9-dione

 napabucasina                          2-acetilnafto[2,3-b]furan-4,9-diona




                                                                                                         97
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




                           C14H8O4

                                        O

                                                    O    CH3

                                                         O
                                        O



 odalasvirum
 odalasvir                 dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane-
                            2 2
                           1 ,4 -diylbis{1H-benzimidazole-5,2-diyl[(2S,3aS,7aS)-
                           octahydro-1H-indole-2,1-diyl][(2S)-3-methyl-1-oxobutan-
                           1,2-diyl]})biscarbamate
                                                                         2       2
 odalasvir                 N,N'-(1,4(1,4)-dibenzénacyclohexaphane-1 ,4 -diylbis{1H-
                           benzimidazole-5,2-diyl[(2S,3aS,7aS)-octahydro-1H-indole-
                           2,1-diyl][(2S)-3-méthyl-1-oxobutan-1,2-diyl]})biscarbamate
                           de diméthyle
                                                                     2   2
 odalasvir                 N,N'-(1,4(1,4)-dibencenaciclohexafano-1 ,4 -diilbis{1H-
                           benzoimidazol-5,2-diil[(2S,3aS,7aS)-octahidro-1H-indol-
                           2,1-diil][(2S)-3-metil-1-oxobutan-1,2-diil]})biscarbamato de
                           dimetilo

                           C60 H72 N8 O6

                                    CH3             O CH                         H
                                            H            3                       N   H
                                            N                                                      H
                              H3C
                                    H               O                            N
                                        H                                                 N
                                                O                                O
                                        N                                                 H
                                                N                            O                H
                                                                                                  CH3
                              H                                                      N
                                            H   N                 H3C O              H
                                                H                                        H3C



 olipudasum alfa #
 olipudase alfa            recombinant DNA derived des-(1-13)-human
                           sphingomyelin phosphodiesterase (acid sphingomyelinase,
                           EC-3.1.4.12), produced in Chinese hamster ovary (CHO)
                           cells, glycoform alfa

 olipudase alfa            dès-(1-13)-sphingomyéline phosphodiesterase humaine
                           (sphingomyélinase acide, EC-3.1.4.12), produite par des
                           cellules ovariennes de hamster chinois à partir d'ADN
                           recombinant, forme glycosylée alfa

 olipudasa alfa            des-(1-13)-esfingomielina fosfodiesterasa humana
                           (esfingomielinasa ácida, EC-3.1.4.12), producida en
                           células ováricas de hamster chino a partir de ADN
                           recombinante, forma glicosilada alfa




98
WHO Drug Information, Vol. 29, No. 1, 2015                                             Recommended INN: List 73



                                       Sequence / Séquence / Secuencia
                                                          HPLSPQG HPARLHRIVP                    RLRDVFGWGN          LTCPICKGLF   50
                                       TAINLGLKKE     PNVARVGSVA IKLCNLLKIA                     PPAVCQSIVH          LFEDDMVEVW   100
                                       RRSVLSPSEA     CGLLLGSTCG HWDIFSSWNI                     SLPTVPKPPP          KPPSPPAPGA   150
                                       PVSRILFLTD     LHWDHDYLEG TDPDCADPLC                     CRRGSGLPPA          SRPGAGYWGE   200
                                       YSKCDLPLRT     LESLLSGLGP AGPFDMVYWT                     GDIPAHDVWH          QTRQDQLRAL   250
                                       TTVTALVRKF     LGPVPVYPAV GNHESTPVNS                     FPPPFIEGNH          SSRWLYEAMA   300
                                       KAWEPWLPAE     ALRTLRIGGF YALSPYPGLR                     LISLNMNFCS          RENFWLLINS   350
                                       TDPAGQLQWL     VGELQAAEDR GDKVHIIGHI                     PPGHCLKSWS          WNYYRIVARY   400
                                       ENTLAAQFFG     HTHVDEFEVF YDEETLSRPL                     AVAFLAPSAT          TYIGLNPGYR   450
                                       VYQIDGNYSG     SSHVVLDHET YILNLTQANI                     PGAIPHWQLL          YRARETYGLP   500
                                       NTLPTAWHNL     VYRMRGDMQL FQTFWFLYHK                     GHPPSEPCGT          PCRLATLCAQ   550
                                       LSARADSPAL     CRHLMPDGSL PEAQSLWPRP                     LFC                              583

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       43-119 46-111 74-85 175-180 181-204 339-385 538-542 548-561

                                       Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                       Asn-40 Asn-129 Asn-289 Asn-349 Asn-457 Asn-474


 omipalisibum
 omipalisib                            2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-
                                       6-yl]pyridin-3-yl}benzenesulfonamide

 omipalisib                            2,4-difluoro-N-{2-méthoxy-5-[4-(pyridazin-4-yl)quinoléin-
                                       6-yl]pyridin-3-yl}benzènesulfonamide

 omipalisib                            2,4-difluoro-N-{2-metoxi-5-[4-(piridazin-4-il)quinolein-
                                       6-il]piridin-3-il}bencenosulfonamida

                                       C25H17F2N5O3S

                                        F                                                               N
                                                                  H
                                                                  N
                                                            S
                                                  F       O O
                                                           H3CO              N
                                                                                                  N
                                                                                                        N

 orilotimodum
 orilotimod                            D-γ-glutamyl-D-tryptophan

 orilotimod                            D-γ-glutamyl-D-tryptophane

 orilotimod                            D-γ-glutamil-D-triptófano

                                       C16H19N3O5

                                                 H     NH2
                                                                         H
                                                                         N           CO2H
                                        HO2C
                                                                    O             H



                                                                                 N
                                                                                 H

 paritaprevirum
 paritaprevir                          (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-
                                       6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-
                                       2-(phenanthridin-6-yloxy)-
                                       1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                                       tetradecahydrocyclopropa[e]pyrrolo[1,2-
                                       a][1,4]diazacyclopentadecine-14a(5H)-carboxamide




                                                                                                                                       99
Recommended INN: List 73             WHO Drug Information, Vol. 29, No. 1, 2015


 paritaprévir              (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-
                           6-(5-méthylpyrazin-2-carboxamido)-5,16-dioxo-
                           2-(phénanthridin-6-yloxy)-
                           1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                           tétradécahydrocyclopropa[e]pyrrolo[1,2-
                           a][1,4]diazacyclopentadécine-14a(5H)-carboxamide

 paritaprevir              (2R,6S,12Z,13aS,14aR,16aS)-N-(ciclopropilsulfonil)-
                           6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-
                           iloxi)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                           tetradecahidrociclopropa[e]pirrolo[1,2-
                           a][1,4]diazaciclopentadecina-14a(5H)-carboxamida

                           C40H43N7O7S
                                     O
                                    O S
                                O     NH
                                           O
                                               H
                                      N                H
                                      H
                                H     O        N       O     N

                                                H O
                                           HN

                                                   N   N

                                                       CH3


 pasotuxizumabum #
 pasotuxizumab             immunoglobulin scFv-scFv, anti-[Homo sapiens FOLH1 (folate
                           hydrolase, prostate specific membrane antigen, PSMA)]/anti-
                           [Homo sapiens CD3E (CD3 epsilon)], humanized and chimeric
                           monoclonal antibody bispecific single chain;
                           scFv anti-FOLH1 (1-243) [humanized VH (Homo sapiens
                           IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-
                           mer tris(tetraglycyl-seryl) linker (122-136) -humanized
                           V-KAPPA (Homo sapiens IGKV1-16*01 (81.10%)-
                           IGKJ2*01Q120>G (236)) [6.3.9](137-243)] -6-mer seryl-
                           tetraglycyl-seryl linker (244-249) -scFv anti-CD3E (250-498)
                           [Mus musculus VH (Mus musculus IGHV10-1*02 (91.90%)-
                           (IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tetraglycyl-
                           seryl) linker (375-389) -humanized
                           V-LAMBDA (Homo sapiens IGLV7-43*01(85.10%)-IGLJ3*02
                           [9.3.9] (390-498)] -hexahistidine (499-504)

 pasotuxizumab             immunoglobuline scFv-scFv, anti-[Homo sapiens FOLH1
                           (folate hydrolase, antigène membranaire spécifique de la
                           prostate, PSMA)]/anti-[Homo sapiens CD3E (CD3 epsilon)],
                           anticorps monoclonal humanisé et chimérique bispécifique à
                           chaîne unique;
                           scFv anti-FOLH1(1-243) [VH humanisé (Homo sapiens IGHV3-
                           11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-mer
                           tris(tétraglycyl-séryl) linker (122-136) - V-KAPPA humanisé
                           (Homo sapiens IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G
                           (236)) [6.3.9](137-243)] -6-mer séryl-tétraglycyl-séryl linker
                           (244-249) -scFv anti-CD3E (250-498) [Mus musculus VH (Mus
                           musculus IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16]
                           (250-374) -15-mer tris(tétraglycyl-séryl) linker (375-389) –
                           V-LAMBDA humanisé (Homo sapiens IGLV7-43*01(85.00%)-
                           IGLJ3*02 [9.3.9] (390-498)] -hexahistidine (499-504)




100
WHO Drug Information, Vol. 29, No. 1, 2015                                        Recommended INN: List 73




 pasotuxizumab                         inmunoglobulina scFv-scFv, anti-[Homo sapiens FOLH1
                                       (folato hidrolasa, antígeno de membrana específico de la
                                       próstata, PSMA)]/anti-[Homo sapiens CD3E (CD3
                                       épsilon)], anticuerpo monoclonal humanizado y quimérico
                                       biespecífico monocatenario;
                                       IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14] (1-121)
                                       -15-mer tris(tetraglicil-seril) conector (122-136) - V-KAPPA
                                       humanizado (Homo sapiens IGKV1-16*01 (81.10%)-
                                       IGKJ2*01Q120>G (236)) [6.3.9] (137-243)] -6-mer seril-
                                       tetraglicil-seril conector (244-249) -scFv anti-CD3E (250-
                                       498) [Mus musculus VH (Mus musculus IGHV10-1*02
                                       (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer
                                       tris(tetraglicil-seril) conector 375-389) -V-LAMBDA
                                       humanizado (Homo sapiens IGLV7-43*01(85.00%)-
                                       IGLJ3*02 [9.3.9] (390-498)] -hexahistidina (499-504)
                                       QVQLVESGGG      LVKPGESLRL       SCAASGFTFS       DYYMYWVRQA       PGKGLEWVAI        50
                                       ISDGGYYTYY      SDIIKGRFTI       SRDNAKNSLY       LQMNSLKAED       TAVYYCARGF       100
                                       PLLRHGAMDY      WGQGTLVTVS       SGGGGSGGGG       SGGGGSDIQM       TQSPSSLSAS       150
                                       VGDRVTITCK      ASQNVDTNVA       WYQQKPGQAP       KSLIYSASYR       YSDVPSRFSG       200
                                       SASGTDFTLT      ISSVQSEDFA       TYYCQQYDSY       PYTFGGGTKL       EIKSGGGGSE       250
                                       VQLVESGGGL      VQPGGSLKLS       CAASGFTFNK       YAMNWVRQAP       GKGLEWVARI       300
                                       RSKYNNYATY      YADSVKDRFT       ISRDDSKNTA       YLQMNNLKTE       DTAVYYCVRH       350
                                       GNFGNSYISY      WAYWGQGTLV       TVSSGGGGSG       GGGSGGGGSQ       TVVTQEPSLT       400
                                       VSPGGTVTLT      CGSSTGAVTS       GNYPNWVQQK       PGQAPRGLIG       GTKFLAPGTP       450
                                       ARFSGSLLGG      KAALTLSGVQ       PEDEAEYYCV       LWYSNRWVFG       GGTKLTVLHH       500
                                       HHHH                                                                                504

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-chain C23 C104 22-96 159-224 271-347 411-479


 patidegibum
 patidegib                             N-[(2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)-
                                       3,6,11',12'b-tetramethyl-
                                       2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-
                                       icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-
                                       naphtho[2,1-a]azulen]-3'-yl]methanesulfonamide

 patidégib                             N-[(2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)-
                                       3,6,11',12'b-tétraméthyl-
                                       2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-
                                       icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-
                                       naphto[2,1-a]azulen]-3'-yl]méthanesulfonamide

 patidegib                             N-[(2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)-
                                       3,6,11',12'b-tetrametil-
                                       2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-
                                       icosahidro-1'H,3H-espiro[furo[3,2-b]piridina-2,9'-nafto[2,1-
                                       a]azulen]-3'-il]metanosulfonamida

                                       C29H48N2O3S

                                                                                            HN                CH3
                                                                                        H H
                                                                         H 3C H 3 C                            H

                                                                                               O     H
                                                                   CH3      H
                                           O O                                  H
                                                                       H
                                            S
                                        H3C   N
                                              H H                  H




                                                                                                                               101
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015




 peficitinibum
 peficitinib               4-{[(1R,2s,3S,5s,7s)-5-hydroxyadamantan-2-yl]amino}-
                           1H-pyrrolo[2,3-b]pyridine-5-carboxamide

 péficitinib               4-{[(1R,2s,3S,5s,7s)-5-hydroxyadamantan-2-yl]amino}-
                           1H-pyrrolo[2,3-b]pyridine-5-carboxamide

 peficitinib               4-{[(1R,2s,3S,5s,7s)-5-hidroxiadamantan-2-il]amino}-
                           1H-pirrolo[2,3-b]piridina-5-carboxamida

                           C18H22N4O2

                                                       H2N        O
                                                   H
                                                   N

                                                                  N
                            HO
                                                             NH

 pegargiminasum #
 pegargiminase             [111-glutamic acid,209-serine]arginine deiminase (ADI,
                           arginine dihydrolase, AD) from Mycoplasma hominis, an
                           average of five amino groups are amidified with
                           4-[ω-methoxypoly(oxyethylene)]-4-oxobutanoyl, produced
                           in Escherichia coli

 pégargiminase             [111-acide glutamique,209-sérine]arginine désiminase
                           (ADI, arginine dihydrolase, AD) de Mycoplasma hominis,
                           produite par Escherichia coli, et dont cinq groupes amino,
                           en moyenne, sont amidifiés par le
                           4-[ω-méthoxypoly(oxyéthylène)]-4-oxobutanoyle

 pegargiminasa             [111-ácido glutámico,209-seria]arginina desiminasa (ADI,
                           arginina dihidrolasa, AD) de Mycoplasma hominis,
                           producida en Escherichia coli, en la cual 5 grupos amino
                           por término medio, están amidificado por
                           4-[ω-metoxipoli(oxietileno)]-4-oxobutanoilo

                           C2091H3276N540O607S15 ((C5H6O3(C2H4O)n)a
                           Sequence / Séquence / Secuencia
                           SVFDSKFNGI HVYSEIGELE TVLVHEPGRE                   IDYITPARLD       ELLFSAILES        50
                           HDARKEHQSF VKIMKDRGIN VVELTDLVAE                   TYDLASKAAK       EEFIETFLEE        100
                           TVPVLTEANK EAVRAFLLSK PTHEMVEFMM                   SGITKYELGV       ESENELIVDP        150
                           MPNLYFTRDP FASVGNGVTI HFMRYIVRRR                   ETLFARFVFR       NHPKLVKTPW        200
                           YYDPAMKMSI EGGDVFIYNN ETLVVGVSER                   TDLDTITLLA       KNIKANKEVE        250
                           FKRIVAINVP KWTNLMHLDT WLTMLDKNKF                   LYSPIANDVF       KFWDYDLVNG        300
                           GAEPQPQLNG LPLDKLLASI INKEPVLIPI                   GGAGATEMEI       ARETNFDGTN        350
                           YLAIKPGLVI GYDRNEKTNA ALKAAGITVL                   PFHGNQLSLG       MGNARCMSMP        400
                           LSRKDVKW                                                                              408

                           Potential modified residues* / Résidus modifiables* / Restos potencialemente modificados*
                             S HO         H                              K                                        H
                             1 R                         6-55-62-65-87-90-110-120-135-194
                                    N      CO2H        197-207-241-244-247-252-261-277-279
                                    H                    291-315-323-355-367-373-404-407                  H2N      CO2H
                                                                                           R        NH
                                                                                      O

                                                R- =     H- or/ou/o H3CO          O             C
                                                                                      n
                                                                                                  O
                            *    an average of 5 (a) out of 28 are pegylated / 5 (a) sur les 28 sont en moyenne pégylés /
                            5 (a) cada 28 por térnino medio están pegilados




102
WHO Drug Information, Vol. 29, No. 1, 2015                                          Recommended INN: List 73


 pegcrisantaspasum #
 pegcrisantaspase                      recombinant L-asparaginase derived from Erwinia
                                       chrysanthemi pegylated with 5 kDa methoxy polyethylene
                                       glycol (m-PEG-NHS), produced in Escherichia coli:
                                       L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase)
                                       Erwinia chrysanthemi tetramer α4, an average of 10 (a) out
                                       of 18 amino groups of each monomer are amidified with
                                       5-{[α-methylpoly(oxyethylene)]amino}-5-oxopentanoyl

 pegcrisantaspase                      L-asparaginase recombinante dérivée d’Erwinia
                                       chrysanthemi pégylée par du méthoxy polyéthylène glycol
                                       (m-PEG-NHS) de 5kDa, produite par Escherichia coli:
                                       tétramère α4 de la L-asparaginase (EC 3.5.1.1,
                                       L-asparagine amidohydrolase) d’Erwinia chrysanthemi dont
                                       10 (a) groupes amino, en moyenne, sur les 18 de chaque
                                       monomère sont amidifiés par le radical substituant 5-{[α-
                                       méthylpoly(oxyéthylène)]amino}-5-oxopentanoyle

 pegcrisantaspasa                      L-asparaginasa recombinante derivada de Erwinia
                                       chrysanthemi pegilada por metoxi polietilenglicol (m-PEG-
                                       NHS) de 5kDa, producida en Escherichia coli:
                                       tetrámero α4 de la L-asparaginasa (EC 3.5.1.1,
                                       L-asparagina amidohidrolasa) d’Erwinia chrysanthemi de la
                                       cual 10 (a) grupos amino, por término medio, de los 18 de
                                       cada monómero están amidificados por 5-{[α-
                                       metilpoli(oxietileno)]amino}-5-oxopentanoilo

                                       C1546H2510N432O476S9(C6H9NO2[C2H4O]n)a (monomer)
                                       Monomer sequence / Séquence du monomère/ Secuencia del monómero
                                       ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI NAVPEVKKLA                              50
                                       NVKGEQFSNM ASENMTGDVV LKLSQRVNEL LARDDVDGVV ITHGTDTVEE                              100
                                       SAYFLHLTVK SDKPVVFVAA MRPATAISAD GPMNLLEAVR VAGDKQSRGR                              150
                                       GVMVVLNDRI GSARYITKTN ASTLDTFKAN EEGYLGVIIG NRIYYQNRID                              200
                                       KLHTTRSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH GVKGIVYAGM                              250
                                       GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG NGIVPPDEEL PGLVSDSLNP                              300
                                       AHARILLMLA LTRTSDPKVI QEYFHTY                                                       327

                                       Potential modified residues / Résidus modifiés potentiels / Restos potencialmente modificados
                                                 H3 C   H                        K
                                         A                       3-30-47-48-53-72-110-113-145-168   R   NH             H
                                         1   R
                                                  N      CO2H      178-201-219-243-265-269-318
                                                  H                                                             H2N    CO2H
                                                                                H
                                         R =H      or / ou / ó   H3C            N
                                                                       O                       C
                                                                                n                            n # 120
                                                                                    O          O


 pegvaliasum #
 pegvaliase                            pegylated, recombinant DNA derived Anabaena variabilis
                                       phenylalanine ammonia lyase mutein (S 503, S 565),
                                       produced in Escherichia coli:
                                       [503,565-diserine (C>S)]phenylalanine ammonia-lyase (EC
                                       4.3.1.24) Anabaena variabilis in which an average of 5
                                                           6
                                       lysyl residues are N -{6-[ω-
                                       methoxypoly(oxyethylene)]hexanoyl} substituted

 pegvaliase                            mutéine (S 503, S 565) de phénylalanine ammoniac-lyase
                                       de Anabaena variabilis, pégylée, produite par Escherichia
                                       coli à partir d'ADN recombinant:
                                       [503,565-disérine (C>S)]phénylalanine ammoniac-lyase
                                       (EC 4.3.1.24) de Anabaena variabilis dont une moyenne
                                                                6
                                       de 5 résidus lysyl sont N -{6-[ω-
                                       méthoxypoly(oxyéthylène)]hexanoyl} substitués




                                                                                                                                 103
Recommended INN: List 73                  WHO Drug Information, Vol. 29, No. 1, 2015


 pegvaliasa                muteína (S 503, S 565) de la fenilalanina amoniaco-liasa
                           de Anabaena variabilis, pegilada, producida en
                           Escherichia coli a partir de ADN recombinante:
                           [503,565-diserine (C>S)]fenilalanina amoniaco-liase (EC
                           4.3.1.24) de Anabaena variabilis de cuyos restos lisil 5, por
                                                    6
                           término medio, están N -{6-[ω-
                           metoxipoli(oxietileno)]hexanoil} substituidos

                           C2726H4321N763O828S20 (C7H12O2[C2H4O]n)a
                           Sequence / Séquence / Secuencia
                           MKTLSQAQSK TSSQQFSFTG NSSANVIIGN                      QKLTINDVAR   VARNGTLVSL        50
                           TNNTDILQGI QASCDYINNA VESGEPIYGV                      TSGFGGMANV   AISREQASEL        100
                           QTNLVWFLKT GAGNKLPLAD VRAAMLLRAN                      SHMRGASGIR   LELIKRMEIF        150
                           LNAGVTPYVY EFGSIGASGD LVPLSYITGS                      LIGLDPSFKV   DFNGKEMDAP        200
                           TALRQLNLSP LTLLPKEGLA MMNGTSVMTG                      IAANCVYDTQ   ILTAIAMGVH        250
                           ALDIQALNGT NQSFHPFIHN SKPHPGQLWA                      ADQMISLLAN   SQLVRDELDG        300
                           KHDYRDHELI QDRYSLRCLP QYLGPIVDGI                      SQIAKQIEIE   INSVTDNPLI        350
                           DVDNQASYHG GNFLGQYVGM GMDHLRYYIG                      LLAKHLDVQI   ALLASPEFSN        400
                           GLPPSLLGNR ERKVNMGLKG LQICGNSIMP                      LLTFYGNSIA   DRFPTHAEQF        450
                           NQNINSQGYT SATLARRSVD IFQNYVAIAL                      MFGVQAVDLR   TYKKTGHYDA        500
                           RASLSPATER LYSAVRHVVG QKPTSDRPYI                      WNDNEQGLDE   HIARISADIA        550
                           AGGVIVQAVQ DILPSLH                                                                   567
                           Modified residues / Résidus modifiés / Restos modificados
                                  ASG
                              167-168-169
                           Dianhydroderivative                                                              H
                                        CH2
                                                                       K
                                                         10, 32, 115, 145, 195, 301,              H2N       CO2H
                                      N                                                  R NH
                                                  O       335, 413, 493, 494, 522
                                H
                                N                           Partly pegylated Lysyl   R- = H- or/ou/o               O
                                          N        O     Lysyl partiellement pégylé
                                                         Lisil parcialmente pegilado      H3CO                     C
                                H CH3                                                                   O   n    4



 polmacoxibum
 polmacoxib                4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-
                           2-yl]-benzenesulfonamide

 polmacoxib                4-[3-(3-fluorophényl)-5,5-diméthyl-4-oxo-4,5-dihydrofuran-
                           2-yl]-benzènesulfonamide

 polmacoxib                4-[3-(3-fluorofenil)-5,5-dimetil-4-oxo-4,5-dihidrofuran-2-il]-
                           bencenosulfonamida

                           C18H16FNO4S

                            F                                  O O
                                                                S
                                                                  NH2


                                O
                                              O
                                H3C
                                          CH3

 presatovirum
 presatovir                N-(2-{[(2S)-2-{5-[(3S)-3-aminopyrrolidin-1-yl]-
                           6-methylpyrazolo[1,5-a]pyrimidin-2-yl}piperidin-
                           1-yl]carbonyl}-4-chlorophenyl)methanesulfonamide

 présatovir                N-(2-{[(2S)-2-{5-[(3S)-3-aminopyrrolidin-1-yl]-
                           6-méthylpyrazolo[1,5-a]pyrimidin-2-yl}pipéridin-
                           1-yl]carbonyl}-4-chlorophényl)méthanesulfonamide




104
WHO Drug Information, Vol. 29, No. 1, 2015                                   Recommended INN: List 73




 presatovir                            N-(2-{[(2S)-2-{5-[(3S)-3-aminopirrolidin-1-il]-
                                       6-metilpirazolo[1,5-a]pirimidin-2-il}piperidin-1-il]carbonil}-
                                       4-clorofenil)metanosulfonamida

                                       C24H30ClN7O3S

                                                    O
                                                       CH3
                                                   O S
                                                        NH
                                                                                          H
                                                                                              NH2
                                                             O
                                        Cl
                                                                 H           N        N
                                                        N
                                                                         N
                                                                     N                CH3


 rabacfosadinum
 rabacfosadine                         diethyl N,N'-[({2-[2-amino-6-(cyclopropylamino)-9H-purin-
                                       9-yl]ethoxy}methyl)phosphinylidene]bis-L-alaninate

 rabacfosadine                         N,N'-[({2-[2-amino-6-(cyclopropylamino)-9H-purin-
                                       9-yl]éthoxy}méthyl)phosphinylidène]bis-L-alaninate de
                                       diéthyle

 rabacfosadina                         N,N'-[({2-[2-amino-6-(ciclopropilamino)-9H-purin-
                                       9-il]etoxi}metil)fosfinilideno]bis-L-alaninato de dietilo

                                       C21H35N8O6P

                                                                                      O
                                                                         H3C
                                                   NH
                                                                          H               O     CH3
                                                            N            O
                                               N                                 NH
                                                                             P
                                                                                 NH
                                        H2N        N        N        O
                                                                         H                O     CH3
                                                                         H3C
                                                                                      O

 rapastinelum
 rapastinel                            L-threonyl-L-prolyl-L-prolyl-L-threoninamide

 rapastinel                            L-thréonyl-L-prolyl-L-prolyl-L-thréoninamide

 rapastinel                            L-treonil-L-prolil-L-prolil-L-treoninamida

                                       C18H31N5O6

                                                                                 HO       CH3
                                                                             O
                                                                 O       H                H
                                                   O         H                                NH2
                                                                                 N
                                         H2N                         N           H
                                                        N                                 O
                                        HO      H
                                               CH3




                                                                                                      105
Recommended INN: List 73                   WHO Drug Information, Vol. 29, No. 1, 2015




 relenopridum
 relenopride               4-amino-N-[(1-{(3S)-3-[(carbamoyl)oxy]-
                           3-(4-fluorophenyl)propyl}-piperidin-4-yl)methyl]-5-chloro-
                           2-methoxybenzamide

 rélénopride               4-amino-N-[(1-{(3S)-3-[(carbamoyl)oxy]-
                           3-(4-fluorophényl)propyl}-pipéridin-4-yl)méthyl]-5-chloro-
                           2-méthoxybenzamide

 relenoprida               4-amino-N-[(1-{(3S)-3-[(carbamoil)oxi]-
                           3-(4-fluorofenil)propil}-piperidin-4-il)metil]-5-cloro-
                           2-metoxibenzamida

                           C24H30ClFN4O4

                                                       O
                              Cl                                                                                             F
                                                             N
                                                             H
                                                                                    N
                            H2N                        OCH3
                                                                                                 O H
                                                                                                            NH2
                                                                                                 O

 reveglucosidasum alfa #
 reveglucosidase alfa      des-(2-7)-human insulin-like growth factor II fusion protein
                           with glycyl-L-alanyl-L-prolyl-human lysosomal alpha-
                           glucosidase (acid maltase, aglucosidase alfa) produced in
                           Chinese hamster ovary (CHO) cells, glycoform alfa

 révéglucosidase alfa      dès-(2-7)-facteur II de croissance humain semblable à
                           l’insuline, protéine de fusion avec la glycyl-L-alanyl-L-prolyl-
                           alpha-glucosidase lysosomiale humaine (maltase acide,
                           aglucosidase alfa), forme gylcosylée alfa produite par des
                           cellules ovariennes de hamster chinois (CHO)

 reveglucosidasa alfa      des-(2-7)-factor II de crecimiento humano semejante a la
                           insulina, proteína de fusión con la glicil-L-alanil-L-prolil-alfa-
                           glucosidasa lisosómica humana (maltasa ácida,
                           aglucosidasa alfa), forma glicosilada alfa, producida por
                           células ováricas de hamster chino (CHO)

                           C4735H7189N1261O1371S38
                           Sequence / Séquence / Secuencia
                           ALCGGELVDT LQFVCGDRGF YFSRPASRVS                  RRSRGIVEEC       CFRSCDLALL       50
                           ETYCATPAKS EGAPAHPGRP RAVPTQCDVP                  PNSRFDCAPD       KAITQEQCEA       100
                           RGCCYIPAKQ GLQGAQMGQP WCFFPPSYPS                  YKLENLSSSE       MGYTATLTRT       150
                           TPTFFPKDIL TLRLDVMMET ENRLHFTIKD                  PANRRYEVPL       ETPHVHSRAP       200
                           SPLYSVEFSE EPFGVIVHRQ LDGRVLLNTT                  VAPLFFADQF       LQLSTSLPSQ       250
                           YITGLAEHLS PLMLSTSWTR ITLWNRDLAP                  TPGANLYGSH       PFYLALEDGG       300
                           SAHGVFLLNS NAMDVVLQPS PALSWRSTGG                  ILDVYIFLGP       EPKSVVQQYL       350
                           DVVGYPFMPP YWGLGFHLCR WGYSSTAITR                  QVVENMTRAH       FPLDVQWNDL       400
                           DYMDSRRDFT FNKDGFRDFP AMVQELHQGG                  RRYMMIVDPA       ISSSGPAGSY       450
                           RPYDEGLRRG VFITNETGQP LIGKVWPGST                  AFPDFTNPTA       LAWWEDMVAE       500
                           FHDQVPFDGM WIDMNEPSNF IRGSEDGCPN                  NELENPPYVP       GVVGGTLQAA       550
                           TICASSHQFL STHYNLHNLY GLTEAIASHR                  ALVKARGTRP       FVISRSTFAG       600
                           HGRYAGHWTG DVWSSWEQLA SSVPEILQFN                  LLGVPLVGAD       VCGFLGNTSE       650
                           ELCVRWTQLG AFYPFMRNHN SLLSLPQEPY                  SFSEPAQQAM       RKALTLRYAL       700
                           LPHLYTLFHQ AHVAGETVAR PLFLEFPKDS                  STWTVDHQLL       WGEALLITPV       750
                           LQAGKAEVTG YFPLGTWYDL QTVPIEALGS                  LPPPPAAPRE       PAIHSEGQWV       800
                           TLPAPLDTIN VHLRAGYIIP LQGPGLTTTE                  SRQQPMALAV       ALTKGGEARG       850
                           ELFWDDGESL EVLERGAYTQ VIFLARNNTI                  VNELVRVTSE       GAGLQLQKVT       900
                           VLGVATAPQQ VLSNGVPVSN FTYSPDTKVL                  DICVSLLMGE       QFLVSWC          947

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           3-41 15-54 40-45 77-103 87-104 98-122 528-553 642-653 933-947

                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-135 Asn-228 Asn-465 Asn-487 Asn-647 Asn-877 Asn-920




106
WHO Drug Information, Vol. 29, No. 1, 2015                            Recommended INN: List 73




 revusiranum
 revusiran                             [(2S,4R)-1-{30-(2-acetamido-2-deoxy-
                                       β-D-galactopyranosyl)-14,14-bis[16-(2-acetamido-2-deoxy-β-D-
                                       galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecyl]-
                                       12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-
                                       hydroxypyrrolidin-2-yl]methyl hydrogen 2'-deoxy-2'-
                                       fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-
                                       fluoroguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-
                                       fluoroadenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-
                                       fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-
                                       fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-
                                       deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-
                                       deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-
                                       O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-
                                       deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-
                                       deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-
                                       deoxy-2'-fluoroadenylate duplex with 2'-O-methyl-P-
                                       thiocytidylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiouridylyl-(5'→3')-2'-
                                       O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-
                                       O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-
                                       O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-
                                       O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-
                                       O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-
                                       methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-
                                       methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-
                                       deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-
                                       (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-
                                       (5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-
                                       (5'→3')-2'-O-methyluridine

 révusiran                             duplex de l’hydrogéno-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                       méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-
                                       méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-
                                       méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                       méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-
                                       déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                                       (3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-
                                       (3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-
                                       (3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-
                                       (3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-
                                       (3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-
                                       fluoroadénylate de [(2S,4R)-1-{30-(2-acétamido-2-déoxy-β-D-
                                       galactopyranosyl)-14,14-bis[16-(2-acétamido-2-déoxy-β-D-
                                       galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadécyl]-
                                       12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-
                                       hydroxypyrrolidin-2-yl]méthyle,avec le 2'-O-méthyl-P-
                                       thiocytidylyl-(5'→3')-2'-déoxy-2'-fluoro-P-thiouridylyl-(5'→3')-2'-
                                       O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-
                                       O-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-
                                       O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-
                                       O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-
                                       O-méthylguanylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-O-
                                       méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-O-
                                       méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-
                                       déoxy-2'-fluorouridylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-
                                       (5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-
                                       (5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-
                                       (5'→3')-2'-O-méthyluridine




                                                                                                     107
Recommended INN: List 73             WHO Drug Information, Vol. 29, No. 1, 2015



 revusirán                 dúplex del hidrógeno-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-O-
                           metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-
                           metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-
                           desoxi-2'-fluoroadenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-
                           (3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-
                           (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-
                           2'-O-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-
                           2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-
                           2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilato de
                           [(2S,4R)-1-{30-(2-acetamido-2-desoxi-β-D-
                           galactopiranosil)-14,14-bis[16-(2-acetamido-2-desoxi-β-D-
                           galactopiranosil)-5,11-dioxo-2,16-dioxa-6,10-
                           diazahexadecil]-12,19,25-trioxo-16,30-dioxa-13,20,24-
                           triazatriacontanoil}-4-hidroxipirolidin-2-il]metilo, con el
                           2'-O-metil-P-tiocitidilil-(5'→3')-2'-desoxi-2'-fluoro-P-
                           tiouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-
                           fluorocitidilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-
                           fluorocitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-
                           fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-
                           fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-
                           metiluridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-
                           fluorocitidilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-
                           fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-
                           desoxi-2'-fluoroguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-
                           desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-
                           desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metiluridina

                           C517H676F22N171O314P43S2

                                  [(3’-5’) U-G-G-G-A-U-U-U-C-A-U-G-U-A-A-C-C-A-A-G-A-R1]
                                           . . . . . . . . . . . . . . . . . . .
                           [(5’-3’) Cs-Us-A-C-C-C-U-A-A-A-G-U-A-C-A-U-U-G-G-U-U-C-U]

                                                                                          O        H
                                                               H
                                                      R        N
                                                                                              N
                             Legend                    R R         O
                             X = 2'-deoxy-2'-fluoro
                             X = 2'-O-methyl                                                      H O
                              - = -PO2H-                                              H       H
                                                                   O    O             N       N        O
                             s- = -POSH-              HO
                                                                            O
                                                                                  O
                                                          HO            N
                                                                        H
                                                                   OH       CH3


 ribociclibum
 ribociclib                7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-
                           2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

 ribociclib                7-cyclopentyl-N,N-diméthyl-2-{[5-(pipérazin-1-yl)pyridin-
                           2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

 ribociclib                7-ciclopentil-N,N-dimetil-2-{[5-(piperazin-1-il)piridin-
                           2-il]amino}-7H-pirrolo[2,3-d]pirimidina-6-carboxamida




108
WHO Drug Information, Vol. 29, No. 1, 2015                                       Recommended INN: List 73




                                       C23H30N8O

                                        HN                                                    H3C
                                                N                                                       N CH3
                                                               N          N

                                                                    N          N         N              O
                                                                    H




 rimiducidum
 rimiducid                             1,1'-{ethane-1,2-diylbis[azanediyl(2-oxoethan-2,1-diyl)oxy-
                                       3,1-phenylene]bis[(1R)-3-(3,4-dimethoxyphenyl)propyl]
                                       bis{(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]-
                                       piperidine-2-carboxylate}

 rimiducid                             bis{(2S)-1-[(2S)-2-(3,4,5-
                                       triméthoxyphényl)butanoyl]pipéridine-2-carboxylate} de
                                       1,1'-{éthane-1,2-diylbis[azanediyl(2-oxoéthan-2,1-diyl)oxy-
                                       3,1-phénylène]bis[(1R)-3-(3,4-diméthoxyphényl)propyl]

 rimiducid                             bis{(2S)-1-[(2S)-2-(3,4,5-trimetoxifenil)butanoil]piperidina-
                                       2-carboxilato} de 1,1'-{etano-1,2-diilbis[azanodiil(2-
                                       oxoetan-2,1-diil)oxi-3,1-fenileno]bis[(1R)-3-(3,4-
                                       dimetoxifenil)propil]

                                       C78H98N4O20

                                                                   OCH3
                                                        H3CO              OCH3
                                                                                                                           OCH3
                                                                                                                                  OCH3

                                                          N          H
                                                    H                    CH3
                                                               O                     O
                                                    O     O                                    O
                                                               H                                            H
                                                                          O              NH                     O      O
                                                                                                            O
                                                                                              H3C                      H
                                                                          O      N                  H           N
                                                                                 H
                                        H3CO
                                               OCH3
                                                                                          H3CO                  OCH3
                                                                                                        OCH3




 rociletinibum
 rociletinib                           N-[3-({2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-
                                       5-(trifluoromethyl)pyrimidin-4-yl}amino)phenyl]prop-
                                       2-enamide

 rocilétinib                           N-[3-({2-[4-(4-acétylpipérazin-1-yl)-2-méthoxyanilino]-
                                       5-(trifluorométhyl)pyrimidin-4-yl}amino)phényl]prop-
                                       2-énamide




                                                                                                                                  109
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015




 rociletinib                    N-[3-({2-[4-(4-acetilpiperazin-1-il)-2-metoxianilino]-
                                5-(trifluorometil)pirimidin-4-il}amino)fenil]prop-2-enamida

                                C27H28F3N7O3

                                         O                                           O
                                 H2C
                                             NH                  CH3             N       CH3
                                                  F3C            O         N
                                                             N

                                                   N     N       N
                                                   H             H




 rurioctocogum alfa pegolum #
 rurioctocog alfa pegol         pegylated recombinant DNA derived human blood
                                coagulation factor VIII, produced in Chinese hamster ovary
                                (CHO cells), glycoform alfa:
                                human blood coagulation factor VIII (antihemophilic factor,
                                procoagulant component)-(1-1648)-peptide associated to
                                (1649-2332)-peptide, glycoform alfa produced in CHO
                                                                        6
                                cells, some of its lysine residues are N substituted with
                                4-[1,3-bis({[α-
                                methylpoly(oxyethylene)]carbamoyl}oxy)propan-
                                2-yloxy]butanoyl radicals

 rurioctocog alfa pégol         facteur VIII de coagulation humain, produit par des cellules
                                ovariennes de hamster chinois à partir d'ADN recombinant,
                                pégylé, forme glycosylée alfa;
                                association des peptides (1-1648)- et (1649-2332)- du
                                facteur VIII de coagulation humain (facteur
                                antihémophilique, composé procoagulant) produite par des
                                cellules ovariennes de hamster chinois sous forme
                                glycosylée alfa dont quelques résidus lysine sont
                                  6
                                N substitués par le radical 4-[1,3-bis({[α-
                                méthylpoly(oxyéthylène)]carbamoyl}oxy)propan-
                                2-yloxy]butanoyle

 rurioctocog alfa pegol         factor VIII de coagulación humano, producido por células
                                ováricas de hamster chino a partir de ADN recombinante,
                                pegilado, forma glicosilada alfa;
                                asociación de péptidos (1-1648)- y (1649-2332)- del factor
                                VIII de coagulación humano (factor antihémofílico,
                                componente procoagulante) producido por células
                                ováricas de hamster chino en forma glicosilada alfa
                                                                        6
                                algunos de cuyos restos lisina están N substituidos por
                                radicales 4-[1,3-bis({[α-
                                metilpoli(oxietileno)]carbamoil}oxi)propan-2-iloxi]butanoilo




110
WHO Drug Information, Vol. 29, No. 1, 2015                                         Recommended INN: List 73



                                       Heavy chain / Chaîne lourde / Cadena pesada
                                       ATRRYYLGAV ELSWDYMQSD LGELPVDARF                  PPRVPKSFPF       NTSVVYKKTL           50
                                       FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                  YDTVVITLKN       MASHPVSLHA           100
                                       VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                  GGSHTYVWQV       LKENGPMASD           150
                                       PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                  EGSLAKEKTQ       TLHKFILLFA           200
                                       VFDEGKSWHS ETKNSLMQDR DAASARAWPK                  MHTVNGYVNR       SLPGLIGCHR           250
                                       KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                  HRQASLEISP       ITFLTAQTLL           300
                                       MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                  EEPQLRMKNN       EEAEDYDDDL           350
                                       TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                  TWVHYIAAEE       EDWDYAPLVL           400
                                       APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                  YTDETFKTRE       AIQHESGILG           450
                                       PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                  TDVRPLYSRR       LPKGVKHLKD           500
                                       FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                  RYYSSFVNME       RDLASGLIGP           550
                                       LLICYKESVD QRGNQIMSDK RNVILFSVFD                  ENRSWYLTEN       IQRFLPNPAG           600
                                       VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                  LHEVAYWYIL       SIGAQTDFLS           650
                                       VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                  SMENPGLWIL       GCHNSDFRNR           700
                                       GMTALLKVSS CDKNTGDYYE DSYEDISAYL                  LSKNNAIEPR       SFSQNSRHPS           750
                                       TRQKQFNATT IPENDIEKTD PWFAHRTPMP                  KIQNVSSSDL       LMLLRQSPTP           800
                                       HGLSLSDLQE AKYETFSDDP SPGAIDSNNS                  LSEMTHFRPQ       LHHSGDMVFT           850
                                       PESGLQLRLN EKLGTTAATE LKKLDFKVSS                  TSNNLISTIP       SDNLAAGTDN           900
                                       TSSLGPPSMP VHYDSQLDTT LFGKKSSPLT                  ESGGPLSLSE       ENNDSKLLES           950
                                       GLMNSQESSW GKNVSSTESG RLFKGKRAHG                  PALLTKDNAL       FKVSISLLKT           1000
                                       NKTSNNSATN RKTHIDGPSL LIENSPSVWQ                  NILESDTEFK       KVTPLIHDRM           1050
                                       LMDKNATALR LNHMSNKTTS SKNMEMVQQK                  KEGPIPPDAQ       NPDMSFFKML           1100
                                       FLPESARWIQ RTHGKNSLNS GQGPSPKQLV                  SLGPEKSVEG       QNFLSEKNKV           1150
                                       VVGKGEFTKD VGLKEMVFPS SRNLFLTNLD                  NLHENNTHNQ       EKKIQEEIEK           1200
                                       KETLIQENVV LPQIHTVTGT KNFMKNLFLL                  STRQNVEGSY       DGAYAPVLQD           1250
                                       FRSLNDSTNR TKKHTAHFSK KGEEENLEGL                  GNQTKQIVEK       YACTTRISPN           1300
                                       TSQQNFVTQR SKRALKQFRL PLEETELEKR                  IIVDDTSTQW       SKNMKHLTPS           1350
                                       TLTQIDYNEK EKGAITQSPL SDCLTRSHSI                  PQANRSPLPI       AKVSSFPSIR           1400
                                       PIYLTRVLFQ DNSSHLPAAS YRKKDSGVQE                  SSHFLQGAKK       NNLSLAILTL           1450
                                       EMTGDQREVG SLGTSATNSV TYKKVENTVL                  PKPDLPKTSG       KVELLPKVHI           1500
                                       YQKDLFPTET SNGSPGHLDL VEGSLLQGTE                  GAIKWNEANR       PGKVPFLRVA           1550
                                       TESSAKTPSK LLDPLAWDNH YGTQIPKEEW                  KSQEKSPEKT       AFKKKDTILS           1600
                                       LNACESNHAI AAINEGQNKP EIEVTWAKQG                  RTERLCSQNP       PVLKRHQR             1648

                                       Light chain / Chaîne légère / Cadena ligera
                                                                                                                  EI           1650
                                       TRTTLQSDQE       EIDYDDTISV        EMKKEDFDIY     DEDENQSPRS       FQKKTRHYFI           1700
                                       AAVERLWDYG       MSSSPHVLRN        RAQSGSVPQF     KKVVFQEFTD       GSFTQPLYRG           1750
                                       ELNEHLGLLG       PYIRAEVEDN        IMVTFRNQAS     RPYSFYSSLI       SYEEDQRQGA           1800
                                       EPRKNFVKPN       ETKTYFWKVQ        HHMAPTKDEF     DCKAWAYFSD       VDLEKDVHSG           1850
                                       LIGPLLVCHT       NTLNPAHGRQ        VTVQEFALFF     TIFDETKSWY       FTENMERNCR           1900
                                       APCNIQMEDP       TFKENYRFHA        INGYIMDTLP     GLVMAQDQRI       RWYLLSMGSN           1950
                                       ENIHSIHFSG       HVFTVRKKEE        YKMALYNLYP     GVFETVEMLP       SKAGIWRVEC           2000
                                       LIGEHLHAGM       STLFLVYSNK        CQTPLGMASG     HIRDFQITAS       GQYGQWAPKL           2050
                                       ARLHYSGSIN       AWSTKEPFSW        IKVDLLAPMI     IHGIKTQGAR       QKFSSLYISQ           2100
                                       FIIMYSLDGK       KWQTYRGNST        GTLMVFFGNV     DSSGIKHNIF       NPPIIARYIR           2150
                                       LHPTHYSIRS       TLRMELMGCD        LNSCSMPLGM     ESKAISDAQI       TASSYFTNMF           2200
                                       ATWSPSKARL       HLQGRSNAWR        PQVNNPKEWL     QVDFQKTMKV       TGVTTQGVKS           2250
                                       LLTSMYVKEF       LISSSQDGHQ        WTLFFQNGKV     KVFQGNQDSF       TPVVNSLDPP           2300
                                       LLTRYLRIHP       QSWVHQIALR        MEVLGCEAQD     LY                                    2332

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

                                       Modified residues / Résidus modifiés / Restos modificados
                                                            Y                             HO    O
                                                346-718-719-723-1664-1680                     S                  H   NH2
                                                        O-sulfoTyr                           O O
                                                                                                                      CO2H

                                                              K*                                             C         = R
                                                                               n # 230
                                                                                                             O
                                                                                                  O
                                       R   NH             H                          H                           H
                                                                    H3C              N       O           O       N              CH3
                                                  H2N       CO2H           O                                               O
                                                                                     n                                          n
                                                                                         O                   O
                                       * potential pegylated residues / résidus pouvant être pégylés / restos potencialmente pegilados

                                       Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                       Asn-41 Asn-239 Asn-582 Asn-757 Asn-784 Asn-828 Asn-900 Asn-943
                                       Asn-963 Asn-1001 Asn-1005 Asn-1055 Asn-1066 Asn-1185 Asn-1255
                                       Asn-1259 Asn-1282 Asn-1300 Asn-1412 Asn-1442 Asn-1810 Asn-2118


 sarolanerum
 sarolaner                             1-{5'-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-
                                       5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]-
                                       3'-H-spiro[azetidine-3,1'-[2]benzofuran]-1-yl}-
                                       2-(methanesulfonyl)ethanone

 sarolaner                             1-{5'-[(5S)-5-(3,5-dichloro-4-fluorophényl)-
                                       5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl]-
                                       3'-H-spiro[azétidine-3,1'-[2]benzofuran]-1-yl}-
                                       2-(méthanesulfonyl)éthanone




                                                                                                                                    111
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




 sarolaner                  1-{5'-[(5S)-5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-
                            4,5-dihidroisoxazol-3-il]-3'-H-espiro[azetidina-
                            3,1'-[2]benzofuran]-1-il}-2-(metilsulfonil)etanona

                            C23H18Cl2F4N2O5S

                                        F3C   O N
                             Cl                                                     O
                                                                                            O
                                                                                        S
                                                                                            CH3
                              F                                         N
                                    Cl                                              O
                                                                    O

 savolitinibum
 savolitinib                1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-
                            1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine

 savolitinib                1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)éthyl]-6-(1-méthyl-
                            1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine

 savolitinib                1-[(1S)-1-(imidazo[1,2-a]piridin-6-il)etil]-6-(1-metil-
                            1H-pirazol-4-il)-1H-1,2,3-triazolo[4,5-b]pirazina

                            C17H15N9
                                                            H
                                        N                                       N
                                                      H3C
                             H 3C   N                                   N
                                                  N         N
                                                                N
                                                  N         N


 sembragilinum
 sembragiline               N-[(3S)-1-{4-[(3-fluorophenyl)methoxy]phenyl}-
                            5-oxopyrrolidin-3-yl]acetamide

 sembragiline               N-[(3S)-1-{4-[(3-fluorophényl)méthoxy]phényl}-
                            5-oxopyrrolidin-3-yl]acétamide

 sembragilina               N-[(3S)-1-{4-[(3-fluorofenil)metoxi]fenil}-5-oxopirrolidin-
                            3-il]acetamida

                            C19H19FN2O3



                                              O
                             F
                                                                                O
                                                                N           H
                                                                            N       CH3
                                                            O               H

 tenofovirum alafenamidum
 tenofovir alafenamide      propan-2-yl N-[(S)-({[(2R)-1-(6-amino-9H-purin-
                            9-yl)propan-2-yl]oxy}methyl)phenoxyphosphinoyl]-
                            L-alaninate




112
WHO Drug Information, Vol. 29, No. 1, 2015                                 Recommended INN: List 73




 ténofovir alafénamide                 N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-
                                       2-yl]oxy}méthyl)phénoxyphosphinoyl]-L-alaninate de
                                       propan-2-yle

 tenofovir alafenamida                 N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-il)propan-
                                       2-il]oxi}metil)fenoxifosfinoil]-L-alaninato de propan-2-ilo

                                       C21H29N6O5P

                                             NH2
                                                                               O       CH3
                                                     N         O       H
                                        N                              N
                                                                   P               O     CH3
                                                                       O     H
                                             N       N    O                CH3

                                                           H
                                                         CH3


 tepotinibum
 tepotinib                             3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-
                                       2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin-
                                       3-yl}benzonitrile

 tépotinib                             3-{1-[(3-{5-[(1-méthylpipéridin-4-yl)méthoxy]pyrimidin-
                                       2-yl}phényl)méthyl]-6-oxo-1,6-dihydropyridazin-
                                       3-yl}benzonitrile

 tepotinib                             3-{1-[(3-{5-[(1-metilpiperidin-4-il)metoxi]pirimidin-
                                       2-il}fenil)metil]-6-oxo-1,6-dihidropiridazin-3-il}benzonitrilo

                                       C29H28N6O2
                                                                                                     CN




                                                                                             N
                                                                       N                     N

                                                                           N                     O
                                                           O
                                                 N
                                        H3C

 tradipitantum
 tradipitant                           {2-[1-{[3,5-bis(trifluoromethyl)phenyl]methyl}-5-(pyridin-
                                       4-yl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}(2-
                                       chlorophenyl)methanone

 tradipitant                           {2-[1-{[3,5-bis(trifluorométhyl)phényl]méthyl}-5-(pyridin-
                                       4-yl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}(2-
                                       chlorophényl)méthanone

 tradipitant                           {2-[1-{[3,5-bis(trifluorometil)fenil]metil}-5-(piridin-4-il)-
                                       1H-1,2,3-triazol-4-il]piridin-3-il}(2-clorofenil)metanona




                                                                                                          113
Recommended INN: List 73            WHO Drug Information, Vol. 29, No. 1, 2015




                           C28H16ClF6N5O

                                               N


                                          N
                                                                         CF3
                                                   N
                                              N N
                                          O
                                                                CF3
                                     Cl




 transcrocetinum
 transcrocetin             all-trans-8,8'-diapocarotene-8,8'-dioic acid

 transcrocétine            acide tout-trans-8,8'-diapocarotène-8,8'-dioïque

 transcrocetina            ácido todo-trans-8,8'-diapocaroteno-8,8'-dioico

                           C20H24O4

                                                                      CH3           CH 3
                            HO2C
                                                                                       CO2H
                                   CH3             CH3




 ulixertinibum
 ulixertinib               4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-
                           N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-
                           2-carboxamide

 ulixertinib               4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-
                           N-[(1S)-1-(3-chlorophényl)-2-hydroxyéthyl]-1H-pyrrole-
                           2-carboxamide

 ulixertinib               4-{5-cloro-2-[(propan-2-il)amino]piridin-4-il}-
                           N-[(1S)-1-(3-clorofenil)-2-hidroxietil]-1H-pirrol-
                           2-carboxamida

                           C21H22Cl2N4O2

                                                                    OH
                                                            O        H
                                                   H
                                                   N                           Cl
                                                                N
                                                                H
                                    CH3
                            H3 C
                                   HN                  Cl
                                          N




114
WHO Drug Information, Vol. 29, No. 1, 2015                           Recommended INN: List 73




 uprosertibum
 uprosertib                            N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-
                                       5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-
                                       2-carboxamide

 uprosertib                            N-[(2S)-1-amino-3-(3,4-difluorophényl)propan-2-yl]-
                                       5-chloro-4-(4-chloro-1-méthyl-1H-pyrazol-5-yl)furan-
                                       2-carboxamide

 uprosertib                            N-[(2S)-1-amino-3-(3,4-difluorofenil)propan-2-il]-5-cloro-
                                       4-(4-cloro-1-metil-1H-pirazol-5-il)furan-2-carboxamida

                                       C18H16Cl2F2N4O2

                                             Cl   Cl
                                                       O
                                                               H
                                                               N               F
                                        N N
                                              CH3          O        H
                                                                   NH2         F




 vanucizumabum #
 vanucizumab                           immunoglobulin recombined G1-kappa/lambda, anti-[Homo
                                       sapiens ANGPT2 (angiopoietin 2, Ang2)]/anti-Homo
                                       sapiens VEGFA (vascular endothelial growth factor A,
                                       VEGF-A, VEGF)], humanized monoclonal antibody;
                                       gamma1 heavy chain anti-ANGPT2 (1-463) [Homo sapiens
                                       VH (Homo sapiens IGHV1-2*02 (100.00%) -(IGHD)-
                                       IGHJ3*02) [8.8.22] (1-129) -Homo sapiens IGKC*01
                                       R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 hinge-
                                       CH2-CH3-CHS (hinge 6-15 (237-246), CH2 (247-356),
                                       CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423)
                                       (357-461), CHS (462-463)) (237-463)], (236-213')-disulfide
                                       with light chain anti-ANGPT2 (1’-213’) [glutaminyl-prolyl-
                                       glycyl (1’-3’) -Homo sapiens V-LAMBDA (Homo sapiens
                                       IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -
                                       linker seryl-seryl (109’-110’) -Homo sapiens IGHG1*01
                                       CH1-hinge (CH1 (111'-208') -hinge (1-5) (209’-213’)];
                                       gamma1 heavy chain anti-VEGFA (1-453) [humanized VH
                                       (Homo sapiens IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01)
                                       [8.8.16] (1-123) -Homo sapiens IGHG1*01 (CH1 (124-
                                       221), hinge (222-236), CH2 (237-346), CH3 S10>C (360),
                                       T22>W (372) (347-451), CHS (452-453)) (124-453)],(226-
                                       214')-disulfide with kappa light chain anti-VEGFA (1’-214’)
                                       [humanized V-KAPPA (Homo sapiens IGKV1-16*01
                                       (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                                       IGKC*01 (108'-214')]; dimer (242-232":245-235":365-360")-
                                       trisdisulfide




                                                                                                115
Recommended INN: List 73            WHO Drug Information, Vol. 29, No. 1, 2015




 vanucizumab               immunoglobuline recombinée G1-kappa/lambda, anti-
                           [Homo sapiens ANGPT2 (angiopoietine 2, Ang2)]/anti-
                           Homo sapiens VEGFA (facteur de croissance A de
                           l’endothélium vasculaire, VEGF-A, VEGF)], anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma1 anti-ANGPT2 (1-463) [Homo
                           sapiens VH (Homo sapiens IGHV1-2*02 (100.00%) -
                           (IGHD)-IGHJ3*02) [8.8.22] (1-129) -Homo sapiens
                           IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -
                           IGHG1*01 charnière-CH2-CH3-CHS (charnière 6-15 (237-
                           246), CH2 (247-356), CH3 Y5>C (365), T22>S (382),
                           L24>A (384), Y86>V (423) (357-461), CHS (462-463))
                           (237-463)], (236-213')-disulfure avec la chaîne légère anti-
                           ANGPT2 (1’-213’) [glutaminyl-prolyl-glycyl (1’-3’) -Homo
                           sapiens V-LAMBDA (Homo sapiens IGLV3-21*02
                           (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -linker séryl-séryl
                           (109’-110’) -Homo sapiens IGHG1*01 CH1-charnière (CH1
                           (111'-208') -charnière (1-5) (209’-213’)];
                           chaîne lourde gamma1 anti-VEGFA (1-453) [VH humanisé
                           (Homo sapiens IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01)
                           [8.8.16] (1-123) -Homo sapiens IGHG1*01 (CH1 (124-
                           221), charnière (222-236), CH2 (237-346), CH3 S10>C
                           (360) T22>W (372) (347-451), CHS (452-453)) (124-
                           453)],(226-214')-disulfure avec la chaîne légère kappa anti-
                           VEGFA (1’-214’) [V-KAPPA humanisé (Homo sapiens
                           IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; dimère (242-232":245-
                           235":365-360")-trisdisulfure

 vanucizumab               inmunoglobulina recombinada G1-kappa/lambda, anti-
                           [Homo sapiens ANGPT2 (angiopoyetina 2, Ang2)]/anti-
                           Homo sapiens VEGFA (factor de crecimiento A del
                           endotelio vascular, VEGF-A, VEGF)], anticuerpo
                           monoclonal humanizado;
                           cadena pesada gamma1 anti-ANGPT2 (1-463) [Homo
                           sapiens VH (Homo sapiens IGHV1-2*02 (100.00%) -
                           (IGHD)-IGHJ3*02) [8.8.22] (1-129) -Homo sapiens
                           IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -
                           IGHG1*01 bisagra-CH2-CH3-CHS (bisagra 6-15 (237-
                           246), CH2 (247-356), CH3 Y5>C (365), T22>S (382),
                           L24>A (384), Y86>V (423) (357-461), CHS (462-463))
                           (237-463)], (236-213')-disulfuro con la cadena ligera anti-
                           ANGPT2 (1’-213’) [glutaminil-prolil-glicil (1’-3’) -Homo
                           sapiens V-LAMBDA (Homo sapiens IGLV3-21*02
                           (100.00%) -IGLJ1*01) [6.3.11] (4'-108') –conector seril-seril
                           (109’-110’) -Homo sapiens IGHG1*01 CH1-bisagra (CH1
                           (111'-208') -bisagra (1-5) (209’-213’)];
                           cadena pesada gamma1 anti-VEGFA (1-453) [VH
                           humanizado (Homo sapiens IGHV3-23*03 (76.80%) -
                           (IGHD)-IGHJ4*01) [8.8.16] (1-123) -Homo sapiens
                           IGHG1*01 (CH1 (124-221), bisagra (222-236), CH2 (237-
                           346), CH3 S10>C (360) T22>W (372) (347-451), CHS
                           (452-453)) (124-453)], (226-214')-disulfuro con la cadena
                           ligera kappa anti-VEGFA (1’-214’) [V-KAPPA humanizado
                           (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9]
                           (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero
                           (242-232":245-235":365-360")-trisdisulfuro




116
WHO Drug Information, Vol. 29, No. 1, 2015                                       Recommended INN: List 73



                                       anti- ANGPT2 Heavy chain / Chaîne lourde / Cadena pesada
                                       QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA                        PGQGLEWMGW        50
                                       INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSRLRSDD                        TAVYYCARSP       100
                                       NPYYYDSSGY YYPGAFDIWG QGTMVTVSSA SVAAPSVFIF                        PPSDEQLKSG       150
                                       TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS                        KDSTYSLSST       200
                                       LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGECDKTH                        TCPPCPAPEL       250
                                       LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                        FNWYVDGVEV       300
                                       HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                        NKALPAPIEK       350
                                       TISKAKGQPR EPQVCTLPPS RDELTKNQVS LSCAVKGFYP                        SDIAVEWESN       400
                                       GQPENNYKTT PPVLDSDGSF FLVSKLTVDK SRWQQGNVFS                        CSVMHEALHN       450
                                       HYTQKSLSLS PGK                                                                      463

                                       anti- ANGPT2 Light chain / Chaîne légère / Cadena ligera
                                       QPGLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG                        QAPVLVVYDD 50
                                       SDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW                        DSSSDHYVFG 100
                                       TGTKVTVLSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK                        DYFPEPVTVS 150
                                       WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT                        YICNVNHKPS 200
                                       NTKVDKKVEP KSC                                                                213

                                       anti-VEGFA Heavy chain / Chaîne lourde / Cadena pesada
                                       EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA                        PGKGLEWVGW        50
                                       INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED                        TAVYYCAKYP       100
                                       HYYGSSHWYF DVWGQGTLVT VSSASTKGPS VFPLAPSSKS                        TSGGTAALGC       150
                                       LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS                        VVTVPSSSLG       200
                                       TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL                        LGGPSVFLFP       250
                                       PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV                        HNAKTKPREE       300
                                       QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK                        TISKAKGQPR       350
                                       EPQVYTLPPC RDELTKNQVS LWCLVKGFYP SDIAVEWESN                        GQPENNYKTT       400
                                       PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN                        HYTQKSLSLS       450
                                       PGK                                                                                 453

                                       anti-VEGFA Light chain / Chaîne légère / Cadena ligera
                                       DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP                        GKAPKVLIYF 50
                                       TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ                        YSTVPWTFGQ 100
                                       GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY                        PREAKVQWKV 150
                                       DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK                        VYACEVTHQG 200
                                       LSSPVTKSFN RGEC                                                               214

                                       Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                       Intra-H (C23-C104) 22-96         156-216       277-337 383-441
                                                             22''-96'' 150''-206'' 267''-327'' 373''-431''
                                       Intra-L (C23-C104) 22'-87' 137'-193'
                                                            23'''-88''' 134'''-194'''
                                       Inter-H-L     236-213' 226''-214'''
                                       Inter-H-H     242-232'' 245-235'' 365-360''

                                       N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                       H CH2 N84.4:
                                       313, 303''


 varlilumabum #
 varlilumab                            immunoglobulin G1-kappa, anti-[Homo sapiens anti-CD27
                                       (TNFRSF7, tumor necrosis factor receptor superfamily
                                       member 7)], Homo sapiens monoclonal antibody;
                                       gamma1 heavy chain (1-452)[Homo sapiens VH (IGHV3-
                                       33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12](1-119) -
                                       IGHG1*01 (CH1 (120-217), hinge (218-232), CH2 (233-
                                       342), CH3 (343-447), CHS (448-449) (120-449) -glycyl-
                                       seryl-seryl (450-452)],(222-214')-disulfide with kappa light
                                       chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01
                                       (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-
                                       214')]; dimer (228-228'':231-231'')-bisdisulfide

 varlilumab                            immunoglobuline G1-kappa, anti-[Homo sapiens anti-CD27
                                       (TNFRSF7, membre 7 de la superfamille des récepteurs
                                       du facteur de nécrose tumorale)], Homo sapiens anticorps
                                       monoclonal;
                                       chaîne lourde gamma1 (1-452)[Homo sapiens VH (IGHV3-
                                       33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12](1-119) -
                                       IGHG1*01 (CH1 (120-217), charnière (218-232), CH2
                                       (233-342), CH3 (343-447), CHS (448-449) (120-449) -
                                       glycyl-séryl-séryl (450-452)], (222-214')-disulfure avec la
                                       chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA
                                       (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -
                                       IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-
                                       bisdisulfure




                                                                                                                              117
Recommended INN: List 73                WHO Drug Information, Vol. 29, No. 1, 2015




 varlilumab                inmunoglobulina G1-kappa, anti-[Homo sapiens anti-CD27
                           (TNFRSF7, miembro 7 de la superfamilia de receptores
                           del factor de necrosis tumoral)] anticuerpo monoclonal de
                           Homo sapiens;
                           cadena pesada gamma1 (1-452) [Homo sapiens VH
                           (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12] (1-
                           119) -IGHG1*01 (CH1 (120-217), bisagra (218-232), CH2
                           (233-342), CH3 (343-447), CHS (448-449) (120-449) -
                           glicil-seril-seril (450-452)], (222-214')-disulfuro con la
                           cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA
                           (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -
                           IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-
                           bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVESGGG VVQPGRSLRL SCAASGFTFS                  SYDMHWVRQA       PGKGLEWVAV        50
                           IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARGS       100
                           GNWGFFDYWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGKG       450
                           SS                                                                                  452

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQGIS                  RWLAWYQQKP       EKAPKSLIYA 50
                           ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YNTYPRTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          146-202       263-323 369-427
                                                 22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L (C23-C104) 23'-88'         134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 222-214' 222''-214'''
                           Inter-H-H (h 11, h 14) 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           299, 299''


 velpatasvirum
 velpatasvir               methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-
                           [(methoxycarbonyl)amino]-2-phenylacetyl}-
                           4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-
                           1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-
                           d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-
                           1-oxobutan-2-yl}carbamate

 velpatasvir               {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-
                           [(méthoxycarbonyl)amino]-2-phénylacétyl}-
                           4-(méthoxyméthyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-
                           1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-
                           d]imidazol-2-yl)-5-méthylpyrrolidin-1-yl]-3-méthyl-
                           1-oxobutan-2-yl}carbamate de méthyle

 velpatasvir               {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-
                           [(metoxicarbonil)amino]-2-fenilacetil}-
                           4-(metoximetil)pirrolidin-2-il]-1H-imidazol-4-il}-
                           1,11-dihidro[2]benzopirano[4',3':6,7]nafto[1,2-d]imidazol-
                           2-il)-5-metilpirrolidin-1-il]-3-metil-1-oxobutan-2-il}carbamato
                           de metilo




118
WHO Drug Information, Vol. 29, No. 1, 2015                                   Recommended INN: List 73


                                       C49H54N8O8

                                                                                                     H
                                                                                                     CH3
                                                                                            H
                                                            CH3                                  N   H CH3
                                                        O                              HN
                                                                             O                  NO            CH3
                                                  HN        O                                            NH
                                                                                                 O
                                                            O
                                                                                                     O CH
                                                  H                                                       3
                                                        N       H    N

                                              O                     HN
                                        H3C
                                                   H



 venetoclaxum
 venetoclax                            4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-
                                       1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-
                                       4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-
                                       b]pyridin-5-yl)oxy]benzamide

 vénétoclax                            4-(4-{[2-(4-chlorophényl)-4,4-diméthylcyclohex-1-én-
                                       1-yl]méthyl}pipérazin-1-yl)-N-[(3-nitro-4-{[(oxan-
                                       4-yl)méthyl]amino}phényl)sulfonyl]-2-[(1H-pyrrolo[2,3-
                                       b]pyridin-5-yl)oxy]benzamide

 venetoclax                            4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-
                                       1-il]metil}piperazin-1-il)-N-[(3-nitro-4-{[(oxan-
                                       4-il)metil]amino}fenil)sulfonil]-2-[(1H-pirrolo[2,3-b]piridin-
                                       5-il)oxi]benzamida

                                       C45H50ClN7O7S

                                                                                   O     O O
                                                                                          S                   NO2
                                                                                        N
                                         H3C                                            H
                                        H3C                              N         O                          NH
                                                                     N

                                                                                        N        O

                                                                                  NH

                                                   Cl



 verinuradum
 verinurad                             2-{[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl}-
                                       2-methylpropanoic acid

 vérinurad                             acide 2-{[3-(4-cyanonaphtalén-1-yl)pyridin-4-yl]sulfanyl}-
                                       2-méthylpropanoïque

 verinurad                             ácido 2-{[3-(4-cianonaftalen-1-il)piridin-4-il]sulfanil}-
                                       2-metilpropanoico




                                                                                                               119
Recommended INN: List 73                 WHO Drug Information, Vol. 29, No. 1, 2015


                            C20H16N2O2S

                                                     H 3C     CH3
                             NC
                                                      S         CO2H




                                                      N



 vonapanitasum
 vonapanitase               recombinant DNA derived type I pancreatic elastase,
                            produced in Pichia pastoris:
                            [26-tryptophan(Arg>Trp),202-leucine(Val>Leu),225-
                            arginine(Gln>Arg)]mature human CELA1 (chymotrypsin-
                            like elastase family member 1, pancreatic elastase 1,
                            elastase 1, EC 3.4.21.36) non-glycosylated

 vonapanitase               élastase pancréatique de type I, produite à partir d'ADN
                            recombinant, produite par Pichia pastoris:
                            [26-tryptophane(Arg>Trp),202-leucine(Val>Leu),225-
                            arginine(Gln>Arg)]CELA1 humaine à maturité (membre 1
                            de la famille des élastases analogues de la chymotrypsine,
                            élastase 1 pancréatique, élastase 1, EC 3.4.21.36) non-
                            glycosylée

 vonapanitasa               elastasa pancreática de tipo I, producida a partir de ADN
                            recombinante, producida por Pichia pastoris:
                            [26-triptófano(Arg>Trp),202-leucina(Val>Leu),225-
                            arginina(Gln>Arg)]CELA1 humana madura (miembro 1 de
                            la familia de elastasas análogas a la quimotripsina,
                            elastasa 1 pancreática, elastasa 1, EC 3.4.21.36) no
                            glicosilada
                            Sequence / Séquence / Secuencia
                            VVGGTEAGRN SWPSQISLQY RSGGSWYHTC                  GGTLIRQNWV       MTAAHCVDYQ       50
                            KTFRVVAGDH NLSQNDGTEQ YVSVQKIVVH                  PYWNSDNVAA       GYDIALLRLA       100
                            QSVTLNSYVQ LGVLPQEGAI LANNSPCYIT                  GWGKTKTNGQ       LAQTLQQAYL       150
                            PSVDYAICSS SSYWGSTVKN TMVCAGGDGV                  RSGCQGDSGG       PLHCLVNGKY       200
                            SLHGVTSFVS SRGCNVSRKP TVFTRVSAYI                  SWINNVIASN                        240

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            30-46 127-194 158-174 184-214



 vorhyaluronidasum alfa #
 vorhyaluronidase alfa      human hyaluronidase PH-20 (hyaluronoglucosaminidase
                            PH-20, sperm adhesion molecule 1, EC 3.2.1.35)
                            precursor-(36-482)-peptide (mature-(1-447)-peptide),
                            produced in Chinese hamster ovary (CHO) DG44dhfr-
                            cells, glycoform alfa

 vorhyaluronidase alfa      hyaluronidase PH-20 humaine (hyaluronoglucosaminidase
                            PH-20, molécule adhésive 1 du sperme, EC 3.2.1.35)
                            précurseur-(36-482)-peptide (à maturité-(1-447)-peptide),
                            produite par des cellules ovariennes de hamster chinois
                            DG44dhfr-, forme glycosylée alfa




120
WHO Drug Information, Vol. 29, No. 1, 2015                                             Recommended INN: List 73


 vorhialuronidasa alfa                     hialuronidasa PH-20 humana (hialuronoglucosaminidasa
                                           PH-20, molécula de adhesión 1 de esperma, EC 3.2.1.35)
                                           precursor-(36-482)-péptido (maduro-(1-447)-péptido),
                                           producida por células ováricas de hamster chino
                                           DG44dhfr-, forma glicosilada alfa

                                            C2327H3553N589O667S20 (protein)
                                            Sequence / Séquence / Secuencia
                                            LNFRAPPVIP NVPFLWAWNA PSEFCLGKFD                  EPLDMSLFSF       IGSPRINATG       50
                                            QGVTIFYVDR LGYYPYIDSI TGVTVNGGIP                  QKISLQDHLD       KAKKDITFYM       100
                                            PVDNLGMAVI DWEEWRPTWA RNWKPKDVYK                  NRSIELVQQQ       NVQLSLTEAT       150
                                            EKAKQEFEKA GKDFLVETIK LGKLLRPNHL                  WGYYLFPDCY       NHHYKKPGYN       200
                                            GSCFNVEIKR NDDLSWLWNE STALYPSIYL                  NTQQSPVAAT       LYVRNRVREA       250
                                            IRVSKIPDAK SPLPVFAYTR IVFTDQVLKF                  LSQDELVYTF       GETVALGASG       300
                                            IVIWGTLSIM RSMKSCLLLD NYMETILNPY                  IINVTLAAKM       CSQVLCQEQG       350
                                            VCIRKNWNSS DYLHLNPDNF AIQLEKGGKF                  TVRGKPTLED       LEQFSEKFYC       400
                                            SCYSTLSCKE KADVKDTDAV DVCIADGVCI                  DAFLKPPMET       EEPQIFY          447

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            25-316 189-203 341-352 346-400 402-408 423-429

                                            Glycosylation sites (N, T) / Sites de glycosylation (N, T) / Posiciones de glicosilación (N, T)
                                            Asn-47 Asn-131 Asn-200 Asn-219 Asn-333 Asn-358 Thr-440




                             AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES



Recommended International Non Proprietary Names (Rec. INN): List 57
Dénominations communes internationales proposées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)
p. 60     beroctocogum alfa #
          beroctocog alfa  replace the description by the following one
          béroctocog alfa  remplacer la description par la suivante
          beroctocog alfa  sustitúyase la descripción por la siguiente

                             human blood-coagulation factor VIII-(1-741)-peptide complex with human
                             blood-coagulation factor VIII-(1649-2332)-peptide
                             combinaison du facteur VIII de coagulation humain-(1-741)-peptide avec le
                             facteur VIII de coagulation humain-(1649-2332)-peptide

                             combinación del factor VIII de coagulación humano-(1-741)-péptido con el
                             factor VIII de coagulación humano-(1649-2332)-péptido




                                                                                                                                   121
Recommended INN: List 73                                              WHO Drug Information, Vol. 29, No. 1, 2015


Recommended International Non Proprietary Names (Rec. INN): List 59
Dénominations communes internationales proposées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 74 &    beroctocogum alfa #
75         beroctocog alfa replace the structure by the following one
           béroctocog alfa remplacer la structure par la suivante
           beroctocog alfa sustitúyase la estructura por la siguiente
                             Heavy chain / Chaîne lourde / Cadena pesada
                             ATRRYYLGAV ELSWDYMQSD LGELPVDARF                  PPRVPKSFPF        NTSVVYKKTL      50
                             FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                  YDTVVITLKN        MASHPVSLHA      100
                             VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                  GGSHTYVWQV        LKENGPMASD      150
                             PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                  EGSLAKEKTQ        TLHKFILLFA      200
                             VFDEGKSWHS ETKNSLMQDR DAASARAWPK                  MHTVNGYVNR        SLPGLIGCHR      250
                             KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                  HRQASLEISP        ITFLTAQTLL      300
                             MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                  EEPQLRMKNN        EEAEDYDDDL      350
                             TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                  TWVHYIAAEE        EDWDYAPLVL      400
                             APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                  YTDETFKTRE        AIQHESGILG      450
                             PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                  TDVRPLYSRR        LPKGVKHLKD      500
                             FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                  RYYSSFVNME        RDLASGLIGP      550
                             LLICYKESVD QRGNQIMSDK RNVILFSVFD                  ENRSWYLTEN        IQRFLPNPAG      600
                             VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                  LHEVAYWYIL        SIGAQTDFLS      650
                             VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                  SMENPGLWIL        GCHNSDFRNR      700
                             GMTALLKVSS CDKNTGDYYE DSYEDISAYL                  LSKNNAIEPR        S               741

                             Light chain / Chaîne légère / Cadena ligera
                                                                                                         EI      1650
                             TRTTLQSDQE      EIDYDDTISV       EMKKEDFDIY       DEDENQSPRS        FQKKTRHYFI      1700
                             AAVERLWDYG      MSSSPHVLRN       RAQSGSVPQF       KKVVFQEFTD        GSFTQPLYRG      1750
                             ELNEHLGLLG      PYIRAEVEDN       IMVTFRNQAS       RPYSFYSSLI        SYEEDQRQGA      1800
                             EPRKNFVKPN      ETKTYFWKVQ       HHMAPTKDEF       DCKAWAYFSD        VDLEKDVHSG      1850
                             LIGPLLVCHT      NTLNPAHGRQ       VTVQEFALFF       TIFDETKSWY        FTENMERNCR      1900
                             APCNIQMEDP      TFKENYRFHA       INGYIMDTLP       GLVMAQDQRI        RWYLLSMGSN      1950
                             ENIHSIHFSG      HVFTVRKKEE       YKMALYNLYP       GVFETVEMLP        SKAGIWRVEC      2000
                             LIGEHLHAGM      STLFLVYSNK       CQTPLGMASG       HIRDFQITAS        GQYGQWAPKL      2050
                             ARLHYSGSIN      AWSTKEPFSW       IKVDLLAPMI       IHGIKTQGAR        QKFSSLYISQ      2100
                             FIIMYSLDGK      KWQTYRGNST       GTLMVFFGNV       DSSGIKHNIF        NPPIIARYIR      2150
                             LHPTHYSIRS      TLRMELMGCD       LNSCSMPLGM       ESKAISDAQI        TASSYFTNMF      2200
                             ATWSPSKARL      HLQGRSNAWR       PQVNNPKEWL       QVDFQKTMKV        TGVTTQGVKS      2250
                             LLTSMYVKEF      LISSSQDGHQ       WTLFFQNGKV       KVFQGNQDSF        TPVVNSLDPP      2300
                             LLTRYLRIHP      QSWVHQIALR       MEVLGCEAQD       LY                                2332

                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                             153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

                             Modified residues / Résidus modifiés / Restos modificados
                                                     Y                             HO        O
                                         346-718-719-723-1664-1680                       S                   H    NH2
                                                 O-sulfoTyr                           O O
                                                                                                                   CO2H
                             Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                             Asn-41 Asn-239 Asn-1810 Asn-2118
                                           delete/supprimer/suprimáse
                                           C3821H5813N1003O1139S35 + C3547H5400N956O1033S35


Recommended International Non Proprietary Names (Rec. INN): List 71
Dénominations communes internationales proposées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)


p. 96     ombitasvirum
          ombitasvir                    replace the chemical name by the following one
          ombitasvir                    remplacer le nom chimique par le suivant
          ombitasvir                    sustitúyase el nombre químico por el siguiente

                                        dimethyl N,N'-([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-
                                        2,5-diyl]bis{4,1-phenyleneazanediylcarbonyl[(2S)-pyrrolidine-
                                        2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate




122
WHO Drug Information, Vol. 29, No. 1, 2015                               Recommended INN: List 73




                                  N,N'-([(2S,5S)-1-(4-tert-butylphényl)pyrrolidine-2,5-diyl]bis{4,1-
                                  phénylèneazanediylcarbonyl[(2S)-pyrrolidine-2,1-diyl][(2S)-3-méthyl-
                                  1-oxobutane-1,2-diyl]})biscarbamate de diméthyle

                                  N,N'-([(2S,5S)-1-(4-terc-butilfenil)pirrolidina-2,5-diil]bis{4,1-
                                  fenilenoazanodiilcarbonil[(2S)-pirrolidina-2,1-diil][(2S)-3-metil-
                                  1-oxobutano-1,2-diil]})biscarbamato de dimetilo



p. 98    paclitaxelum trevatidum
& 99     paclitaxel trevatide    replace the chemical name by the following one
         paclitaxel trévatide    remplacer le nom chimique par le suivant
         paclitaxel trevatida    sustitúyase el nombre químico por el siguiente

                                  short modified fragment of human amyloid beta A4 protein
                                  covalently linked to three molecules of paclitaxel through succinyl
                                  linkers:
                                    2.1 6.10 6.15
                                  N ,N ,N -tris(4-{[(1S,2R)-1-benzamido-3-{[4,10β-bis(acetyloxy)-
                                  2α-(benzoyloxy)-5β,20-epoxy-1,7β-dihydroxy-9-oxotax-11-en-13α-
                                  yl]oxy}-3-oxo-1-phenylpropan-2-yl]oxy}-4-oxobutanoyl) ([318-L-
                                  threonine(P>T1),324-L-serine(C>S7),325-L-arginine(G>R8),327-L-
                                  lysine(N>K10),332-L-lysine(D>K15)] human amyloid beta A4 protein
                                  precursor-(318-336)-peptide)

                                  fragment court et modifié de la protéine bêta A4 amyloïde humaine
                                  lié de façon covalente à trois molécules de paclitaxel par autant de
                                  succinyles :
                                    2.1  6.10 6.15
                                  N ,N ,N -tris(4-{[(1S,2R)-1-benzamido-3-{[4,10β-bis(acétyloxy)-
                                  2α-(benzoyloxy)-5β,20-époxy-1,7β-dihydroxy-9-oxotax-11-en-13α-
                                  yl]oxy}-3-oxo-1-phénylpropan-2-yl]oxy}-4-oxobutanoyl) ([318-L-
                                  thréonine(P>T1),324-L-sérine(C>S7),325-L-arginine(G>R8),327-L-
                                  lysine(N>K10),332-L-lysine(D>K15)] précurseur de la protéine
                                  amyloïde bêta A4 humaine-(318-336)-peptide)

                                  fragmento corto y modificado de la proteína beta A4 amiloide
                                  humana unido covalentemente a tres moléculas de paclitaxel
                                  mediante succinilos :
                                     2.1  6.10 6.15
                                  N ,N ,N -tris(4-{[(1S,2R)-1-benzamido-3-{[4,10β-bis(acetiloxi)-
                                  2α-(benzoiloxi)-5β,20-epoxi-1,7β-dihidroxi-9-oxotax-11-en-13α-
                                  il]oxi}-3-oxo-1-fenilpropan-2-il]oxi}-4-oxobutanoil) ([318-L-
                                  treonina(P>T1),324-L-serina(C>S7),325-L-arginina(G>R8),327-L-
                                  lisina(N>K10),332-L-lisina(D>K15)] precursor de la proteína
                                  amiloide beta A4 humana-(318-336)-péptido



p. 115   vedroprevirum
         vedroprevir               replace the chemical name by the following one
         védroprévir               remplacer le nom chimique par le suivant
         vedroprevir               sustitúyase el nombre químico por el siguiente

                                   (1R,2R)-1-{(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-bicyclo[3.1.0]hexan-
                                   3-yl]oxy}carbonyl)amino]-3,3-dimethylbutanoyl}-4-[(8-chloro-
                                   7-[2-(morpholin-4-yl)ethoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-
                                   4-yl}quinolin-4-yl)oxy]pyrrolidine-2-carboxamido}-
                                   2-ethylcyclopropane-1-carboxylic acid




                                                                                                       123
Recommended INN: List 73                                 WHO Drug Information, Vol. 29, No. 1, 2015



                                        acide (1R,2R)-1-{(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-
                                        bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-
                                        3,3-diméthylbutanoyl}-4-[(8-chloro-7-[2-(morpholin-4-yl)éthoxy]-
                                        2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinoléin-
                                        4-yl)oxy]pyrrolidine-2-carboxamido}-2-éthylcyclopropane-
                                        1-carboxylique

                                        ácido (1R,2R)-1-{(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-
                                        biciclo[3.1.0]hexan-3-il]oxi}carbonil)amino]-3,3-dimetilbutanoil}-
                                        4-[(8-cloro-7-[2-(morfolin-4-il)etoxi]-2-{2-[(propan-2-il)amino]-
                                        1,3-tiazol-4-il}quinolin-4-il)oxi]pirrolidina-2-carboxamido}-
                                        2-etilciclopropano-1-carboxílico




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
 
* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf




   Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios
   generales
   The text of the Procedures for the Selection of Recommended International Nonproprietary Names
   for Pharmaceutical Substances and General Principles for Guidance in Devising International
   Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists
   only.
   Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales
   recommandées pour les substances pharmaceutiques et des Directives générales pour la
   formation de dénominations communes internationales applicables aux substances
   pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
   El texto de los Procedimientos de selección de denominaciones comunes internacionales
   recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para
   formar denominaciones comunes internacionales para sustancias farmacéuticas aparece
   solamente en las listas de DCI propuestas.



124
